DR. Tattoff 10-K 15 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 01, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	DR. TATTOFF, INC.
Entity Central Index Key	1294157
Trading Symbol	tatf
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		19,253,880
Entity Public Float			$0
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$32,767	$197,523
Prepaid expenses and other current assets	72,736	397,115
Total current assets	105,503	594,638
Property and Equipment, net	1,984,201	2,050,287
Other Assets	161,487	251,270
Total assets	2,251,191	2,896,195
CURRENT LIABILITIES
Revolving line of credit	1,069,302	1,100,954
Accounts payable	1,027,331	869,313
Related party payables	290,567	23,622
Accrued expenses and other liabilities	601,068	496,053
Accrued compensation	547,876	543,251
Accrued interest	51,269	91,545
Warrant liabilities	24,260	116,690
Deferred revenue	1,529,413	1,113,883
Notes payable, current portion (net of unamortized discount)	1,067,530	716,531
Convertible promissory notes, current portion (net of unamortized discount)	373,051	947,987
Capital lease obligations, current portion (related party)	11,323	10,286
Total current liabilities	6,592,990	6,030,115
LONG-TERM LIABILITIES
Notes payable, net of current portion	1,729,206	255,456
Convertible promissory notes, net of current portion and unamortized discount	1,167,500	328,388
Capital lease obligations, net of current portion (related party)	32,307	43,630
Accrued interest	2,302,462
Deferred rent	287,852	251,597
Total liabilities	12,112,317	6,909,186
COMMITMENTS AND CONTINGENCIES (notes 8 and 10)
SHAREHOLDERS' DEFICIT
Preferred stock, 2,857,143 shares authorized, none issued or outstanding at December 31, 2014 and 2013
Common stock, $.0001 par value, 75,000,000 shares authorized, 19,268,730 and 19,308,230 shares issued and outstanding at December 31, 2014 and 2013, respectively	1,927	1,931
Additional paid-in capital	8,434,783	7,692,978
Accumulated deficit	-18,297,836	-11,707,900
Total shareholders' deficit	-9,861,126	-4,012,991
Total liabilities and shareholders' deficit	$2,251,191	$2,896,195

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]
Preferred stock, shares authorized	2,857,143	2,857,143
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	19,268,730	19,308,230
Common stock, shares outstanding	19,268,730	19,308,230

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues from related party	$2,684,381	$2,547,021
Owned clinic revenues	1,630,032	1,107,579
Total revenues	4,314,413	3,654,600
Operating costs and expenses
Clinic operating expenses	3,699,344	3,353,765
General and administrative expenses	2,365,514	2,911,503
Marketing and advertising	592,737	776,064
Depreciation and amortization	542,695	397,413
Total operating costs and expenses	7,200,290	7,438,745
Loss from operations	-2,885,877	-3,784,145
Interest expense and costs of financing	-3,828,256	-587,148
Gain on sale of property and equipment	22,018	62,366
Change in value of warrant liabilities	106,042	9,184
Loss before provision for income taxes	-6,586,073	-4,299,743
Provision for income taxes	3,863	800
Net Loss	($6,589,936)	($4,300,543)
Basic and diluted net loss per share applicable to common shareholders (in dollars per share)	($0.33)	($0.23)
Weighted average shares outstanding - basic and diluted (in shares)	20,106,722	18,743,738

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (USD $)	Common Stock	Additional Paid-in Capital (Deficit)	Accumulated deficit	Total
BALANCE at Dec. 31, 2012	$1,833	$6,599,446	($7,407,357)	($806,078)
BALANCE (in shares) at Dec. 31, 2012	18,332,803
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Services paid in stock	71	349,848		349,919
Services paid in stock (in shares)	712,452
Stock compensation expense		136,151		136,151
Warrants issued for consulting service		116,824		116,824
Stock options exercised	4	17,489		17,493
Stock options exercised (in shares)	35,700
Common stock issued	23	124,978		125,001
Common stock issued (in shares)	227,275
Beneficial conversion feature on convertible notes		14,000		14,000
Warrants issued with convertible notes		334,242		334,242
Net loss			-4,300,543	-4,300,543
BALANCE at Dec. 31, 2013	1,931	7,692,978	-11,707,900	-4,012,991
BALANCE (in shares) at Dec. 31, 2013	19,308,230			19,308,230
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Fair value of warrants issued on debt extension		413,701		413,701
Stock compensation expense		68,699		68,699
Common stock issued	201	980,443		980,644
Common stock issued (in shares)	2,010,500
Common stock repurchased	-5	-61,238		-61,243
Common stock repurchased (in shares)	-50,000
Share redemption in restructuring of loan	-200	-659,800		-660,000
Share redemption in restructuring of loan (in shares)	-2,000,000
Net loss			-6,589,936	-6,589,936
BALANCE at Dec. 31, 2014	$1,927	$8,434,783	($18,297,836)	($9,861,126)
BALANCE (in shares) at Dec. 31, 2014	19,268,730			19,268,730

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($6,589,936)	($4,300,543)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	542,695	397,413
Amortization of debt discount to interest	693,975	308,633
Non-cash interest and costs of financing	2,617,961
Stock compensation expense	68,699	136,151
Change in fair value of warrant liability	-106,042	-7,415
Impairment charge	39,886
Loss on sale of equipment	40,637
Services paid for in stock and warrants	5,145	466,744
Changes in operating assets and liabilities:
Management fee due from related party		189,484
Prepaid expenses and other current assets	470,394	-126,330
Other assets	81,608	-28,863
Accounts payable	158,017	365,239
Accrued expenses and other liabilities	104,558	9,752
Deferred revenue	415,530	611,088
Related party payable	266,945	23,622
Accrued compensation	4,625	305,894
Accrued interest	-40,276	74,017
Deferred rent	36,256	-53,143
Net cash used in operating activities	-1,189,323	-1,628,257
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	-421,374	-593,059
Proceeds received from sale of property and equipment	87,500
Net cash used in investing activities	-333,874	-593,059
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on capital lease obligations	-10,286	-117,617
Principal payments on notes payable	-501,534	-430,386
Proceeds from sale of common stock		125,001
Repurchase of common stock	-61,243
Proceeds received from issuance of convertible notes	100,000	885,000
Proceeds received from issuance of short-term notes	1,988,156	520,000
Repayment of short-term notes	-125,000
Proceeds received from revolving line of credit	4,168,602	1,301,000
Repayments on revolving line of credit	-4,200,254	-200,046
Proceeds from exercise of stock options		17,493
Net cash provided by financing activities	1,358,441	2,100,445
Net (decrease) increase in cash and cash equivalents	-164,756	-120,871
Cash and cash equivalents - beginning of year	197,523	318,394
Cash and cash equivalents - end of year	32,767	197,523
Cash paid during the year for:
Interest	282,961	135,972
Taxes	3,863	800
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Acquisition of property and equipment through issuance of notes payable	214,625	535,222
Non-cash financing related to revolving line of credit		129,301
Financing of insurance premiums	$146,015	$131,859

ORGANIZATION_AND_NATURE_OF_OPE

ORGANIZATION AND NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1.              ORGANIZATION AND NATURE OF OPERATIONS
	Organization
	Dr. Tattoff, Inc., a Florida corporation formed in 2004, directly and through its wholly-owned subsidiaries, DRTHC I, LLC and DRTHC II, LLC, Delaware limited liability companies (collectively with Dr. Tattoff, Inc., the “Company”) operates clinics and provides marketing and practice management services to licensed physicians who primarily perform laser tattoo removal services. The Company currently operates clinics in Dallas and Houston, Texas; Phoenix, Arizona; and Atlanta, Georgia, and provides services under a management services agreement with a contracting physician at four Southern California locations whereby the Company provides management, administrative, marketing and support services, insurance, and equipment at the clinical sites. The contracting physician’s medical personnel provide laser tattoo and hair removal services.
	In February 2008, the Company completed a reverse merger with Lifesciences Opportunities Incorporated a “public shell” company, and became a Securities and Exchange Commission (“SEC”) registrant (the “Merger”). The Company filed Form 10-Q for the quarters ended March 31, 2008 and June 30, 2008, but failed to file any Forms 10-Q or 10-K subsequently. On March 16, 2010, the Company filed a Form 15 with the SEC to terminate its registration under Section 12(g) of the Securities Exchanges Act of 1934, as amended, (the “Exchange Act”). Upon the filing of the Form 15, the Company’s obligation to file periodic and other reports with the SEC was immediately suspended. On December 7, 2011 the Company filed a registration statement on Form 10 with the SEC to register its common stock pursuant to Section 12(g) of the Exchange Act, which was subsequently amended on December 23, 2011 and January 20, 2012. The amended registration statement became effective on February 6, 2012.
	Increase in Authorized Shares and Reverse Stock Split
	In February 2011, the Company amended its Articles of Incorporation to increase the number of authorized shares to 28,571,429, consisting of 25,714,286 shares of common stock, par value $.0001 per share and 2,857,143 shares of preferred stock. Series of preferred stock may be created and issued from time to time, with such designations, preferences, rights and restrictions as shall be stated in resolutions adopted by the Board of Directors.
	In February 2012, the Company amended its Articles of Incorporation to effect a 7-for-1 reverse stock split. Earnings per share amounts, weighted average common shares outstanding, shares issued and outstanding, exercise prices, and fair value per share amounts for all periods have been adjusted to reflect the Company’s 7-for-1 reverse stock split. Par value per share was unchanged with the difference between the originally calculated par value of issued and outstanding shares and the adjusted amounts reclassified to additional paid-in capital for all periods.
	In June 2012, the Company amended its Articles of Incorporation to increase the number of shares of the Company’s common stock authorized for issuance from 25,714,286 shares to 75,000,000 shares.
	Going Concern
	The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the ordinary course of business. At December 31, 2014, the Company has accumulated losses approximating $18,298,000, current liabilities that exceeded its current assets by approximately $6,487,000, shareholders’ deficit of approximately $9,861,000, and has not yet produced operating income or positive cash flows from operations. The Company’s ability to continue as a going concern is predicated on its ability to raise additional capital, increase sales and margins, and ultimately achieve sustained profitable operations. The uncertainty related to these conditions raises substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Management believes that the Company will need to continue to raise additional outside capital to expand the number of clinics in operation and to address its losses and ability to continue to operate. The Company intends to raise additional capital and continue opening additional clinics to achieve this goal. In addition, the Company expanded its Board of Directors in 2010 to include individuals with substantial experience in raising capital and numerous relationships that may assist the Company in achieving its goals. In the event that the Company is unsuccessful in raising adequate equity capital, management will attempt to reduce losses and preserve as much liquidity as possible. Steps management would likely take would include limiting capital expenditures, reducing expenses and leveraging the relatively few assets that it owns without encumbrance. A reduction in expenses would likely include personnel costs, professional fees, and marketing expenses. While management would attempt to achieve break-even or profitable operations through these steps, there can be no assurance that it will be successful.
	Consolidation Policy
	The Company has various contractual relationships with William Kirby, D.O., Inc. including a management services agreement, medical director’s agreement, and equipment arrangements. The Company evaluated the various relationships between the parties to determine if it should consolidate William Kirby, D.O., Inc. as a variable interest entity pursuant to ASC 810, Consolidation. The Company determined that it was not the primary beneficiary of the interest due to the following: William Kirby, D.O., Inc. has the ability to control the activities that have the most significant impact on its economic performance; the Company does not have an obligation to absorb losses of William Kirby, D.O., Inc.; the Company is not guaranteed a return; and there are no interests that are subordinate to the equity interest at risk. The Company conclusion followed an analysis of both the contractual arrangements and California state law restrictions on relationships between licensed professionals and businesses. Among the restrictions of California law the Company considered most relevant in its analysis were those that prohibit a lay corporation from providing medical services, including laser tattoo and laser hair removal, employing medical personnel, and making key decisions about equipment and marketing initiatives. Therefore, the results of William Kirby, D.O., Inc. are not consolidated into the results of the Company.
	The carrying amount and classification of assets and liabilities in the accompanying consolidated balance sheets relating to the Company’s relationship with William Kirby, D.O., Inc. are summarized as follows:
		December 31,
		2014		2013
	Current Liabilities
	Related party payables	$	290,567	$	23,622
	Capital lease obligations, current portion		11,323		10,286
	Long-Term Liabilities
	Capital lease obligations, net of current portion		32,307		43,630
	The Company may be exposed to losses under its relationship with William Kirby, D.O., Inc. The Company’s most significant exposure to loss in the relationship is under the management services agreement. Losses could occur if the management fees are inadequate to cover the Company’s costs of providing the management services. The Company is unable to estimate its maximum exposure to such losses.
	The Company’s relationship and agreements with William Kirby, D.O., Inc. and Dr. Kirby are further described in Note 7, “Capital Lease Obligations (Related Party)”; Note 8, “Related Party Transactions” and Note 10, “Commitments and Contingencies.”
	Dr. Tattoff, Inc. formed two wholly owned subsidiaries, DRTHC I, LLC and DRTHC II, LLC that are responsible for the operations of some of the new clinics that the Company has established. The consolidated financial statements include the accounts of DRTHC I, LLC and DRTHC II, LLC.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2.              SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying consolidated financial statements of Dr. Tattoff, Inc. and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
	Cash and Cash Equivalents
	The Company considers all highly liquid short-term investments with original maturity of three months or less to be cash equivalents.
	Fair Value of Financial Instruments
	The Company adopted the fair value measurement and disclosure requirements of ASC 820, Fair Value Measurements and Disclosure for financial assets and liabilities measured on a recurring basis. ASC 820 defines fair value, establishes a framework for measuring fair value under GAAP and expands disclosures about fair value measurements. This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820 does not require any new fair value measurements.
	Fair value is defined in ASC 820 as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The standard describes three levels of inputs that may be used to measure fair value:
	Level 1:             Quoted prices in active markets for identical or similar assets and liabilities.
	Level 2:             Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
	Level 3:             Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial instruments include cash and cash equivalents, prepaid expenses and other current assets, other assets, accounts payable, related party payable, accrued expenses and other liabilities, deferred revenue, accrued compensation, capital lease obligations, convertible promissory notes, notes payable, and warrant liabilities.  The carrying amounts of prepaid expenses and other current assets, other assets, accounts payable, related party payable, accrued expenses and other liabilities, deferred revenue and accrued compensation approximate their fair values due to the short maturity of these instruments.  The carrying amounts of capital leases, convertible promissory notes, and notes payable approximates their fair value as these instruments earn or are charged interest based on prevailing rates. The fair value of warrants is measured using level 3 inputs.
	Long-lived Assets
	Long-lived assets are reviewed for impairment in accordance with ASC No. 360 “Accounting for the Impairment or Disposal of Long-Lived Assets,” which requires impairment losses to be recorded on long-lived assets when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of the impairment review, assets are reviewed on an asset-by-asset basis. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of each asset to future net cash flows on an undiscounted basis expected to be generated by such asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount which the carrying amount of the assets on an undiscounted basis exceeds the fair value of the assets.
	The major long-lived assets of the Company are the lasers and Intense Pulse Light, or IPL, devices. While the Company has sustained losses, the clinics where the lasers and IPL devices are located are or are expected to be profitable. As a result, recoverability of assets to be held and used is measured by a comparison of the carrying amount of each asset to future net cash flows on an undiscounted basis expected to be generated by such asset in each clinic. There were no impairments of long-lived assets at December 31, 2013. In February 2014, the Company decided to close its Sugar Land, Texas (a suburb of Houston) clinic due to poor financial performance. The Company concluded that the capitalized tenant improvements were impaired and recorded an impairment charge of approximately $40,000 related to the closure. The impairment charge is included in clinic operating expenses in the accompanying consolidated statements of operations. The Company moved the laser and other capital assets located there to other clinics. In February 2015, the Company entered into a mutual release and settlement agreement with the landlord pursuant to which the Company agreed to make payments totaling $87,000 over a period of two years to the landlord. There have been no other impairments in 2014.
	Property and Equipment
	Property and equipment is recorded at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets. The Company uses the following estimated useful lives for computing depreciation expense: furniture and fixtures, 7 years; medical equipment, 7 years; other equipment, 3 to 5 years. Amortization of leasehold improvements is recorded using the straight-line method based on the lesser of the useful life of the improvement or the lease term, which is typically five years or less.
	Debt and Other Financial Instruments
	Debt/Equity Instruments Issued with Warrants
	The Company estimates the relative fair values of the debt and warrants, and allocates the proceeds pro-rata based on these values. The allocation of proceeds to the warrants results in the debt instrument being recorded at a discount from the face amount of the debt and the value allocated to the warrant is recorded to additional paid-in capital.
	The Company reviews the terms of convertible financial instruments it issues to determine whether there are embedded derivative instruments, including the conversion option that may be required to be bifurcated and accounted for separately as a derivative financial instrument. In circumstances where the convertible instrument contains more than one embedded derivative, including the conversion option that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	When the convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds from the convertible host instruments are first allocated to the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, resulting in those instruments being recorded at a discount from their face value.
	Derivative Financial Instruments
	Derivative instruments are initially recorded at estimated fair value and are then revalued at each reporting date with changes in the estimated fair value reported as charges or credits to income.
	Revenue Recognition
	Currently, the majority of the Company’s revenues are derived from management services provided to William Kirby D.O., Inc., a related party, for our non-owned clinics. The Company provides nonmedical services and facilities based on contractual prices established in advance that extend continuously over a set time for a fixed percentage of the contracting physician’s gross revenues (as defined in the Management Services Agreement - See Note 8, “Related Party Transactions”) with no upfront fees paid by William Kirby D.O., Inc. The management services agreement with William Kirby D.O., Inc. covers all of the Company’s California locations.
	Under the management service agreement with William Kirby D.O., Inc., there is no right to refund or rejection of services. The Company recognizes revenue when the following criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Management services fees are paid by the contracting physician to the Company on a bi-weekly basis as earned, which is when the Company has substantially performed management services pursuant to the terms of the management services agreement with William Kirby D.O., Inc.
	The Company operates the Dallas, Houston, Atlanta and Phoenix locations directly, not pursuant to a management services agreement with a physician. Accordingly, patients contract with the Company and pay for the services they receive directly to the Company. The Company recognizes revenue when the following criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. The Company requires payment at the time of the patient visit or in advance of the visit by those patients purchasing packages of treatments. Payments by patients made in advance of service delivery are recorded as “deferred revenue” on the accompanying consolidated balance sheets and amounted to approximately $1,529,000 at December 31, 2014 and $1,114,000 at December 31, 2013.
	Patients who purchase a package of tattoo removal services at clinics the Company operates directly are eligible to participate in the Company’s tattoo removal guarantee program. Pursuant to the guarantee program, if the tattoo is not fully removed within the recommended number of treatments, the Company will continue to provide additional treatments, consistent with the Company’s medical protocols, for a period of up to one year following the date of the last paid treatment. The Company estimates the cost of the guarantee program based on historical usage and the average cost of treatments. The cost of the program is accrued on a per visit basis as visits occur and is included in clinic operating expense on the accompanying consolidated statements of operations. The Company recognized accrued expense of approximately $132,000 and $77,000 as of December 31, 2014 and December 31, 2013, respectively, related to the guarantee program, and this is included in the accrued expenses and other liabilities in the accompanying consolidated balance sheets. Patients who purchase a package of services and experience complete removal prior to completion of the package are eligible for a refund for the unused portion of the package. The Company recognizes refunds, which have been immaterial in amount, as a reduction in revenue as incurred. Patients who receive services in clinics operated under the management services agreement with William Kirby, D.O., Inc. are eligible for similar programs, which may reduce the management fee that the Company receives.
	Advertising Costs
	Advertising costs are expensed as incurred. For the years ended December 31, 2014 and 2013, advertising expense was approximately $465,000 and $570,000, respectively, and is included in marketing and advertising in the accompanying consolidated statement of operations.
	Income Taxes
	The Company accounts for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740 “Income taxes.” Under ASC 740, deferred income taxes are recognized to reflect the tax consequences in future years for the differences between the amounts of assets and liabilities recognized for financial reporting purposes and such amounts recognized for income tax reporting purposes using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce net deferred tax assets to amounts that are more likely than not to be realized.
	The Company has incurred tax net operating losses since inception and, accordingly, has a deferred tax asset related to such tax net operating loss carryforwards. The Company has provided a 100% valuation allowance on such deferred tax asset at December 31, 2014 and 2013 (See Note 11, “Income Taxes”).
	The Company accounts for uncertainty in income taxes in accordance with ASC 740-10, which prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740-10 also provides guidance on the measurement, derecognition, classification and disclosure of tax positions, as well as the accounting for related interest and penalties. The Company’s policy is to recognize interest and penalties that would be assessed in relation to the settlement value of unrecognized tax benefits as a component of income tax expense. The Company has recognized no tax related interest or penalties since the adoption of ASC 740-10. As of December 31, 2014, the open tax years of the Company were 2009 to 2014.
	Earnings Per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. In computing diluted earnings per share, the treasury stock method assumes that outstanding options are exercised and the proceeds are used to purchase common stock at the average market price during the period. Options will have a dilutive effect under the treasury stock method only when the Company reports net income and the average market price of the common stock during the period exceeds the exercise price of the options. Options, warrants and conversions of convertible debt instruments were not included in computing diluted earnings per share for the years ended December 31, 2014 and 2013, respectively because their effects were antidilutive.
	The following table illustrates the computation of basic and diluted earnings per share:
		2014			2013
	Net loss available to common stockholders (numerator)	$	(6,589,936	)	$	(4,300,543	)
	Weighted average shares outstanding (denominator)		20,106,722			18,743,738
	Basic and diluted EPS	$	(.33	)	$	(.23	)
	Basic and diluted EPS are the same for all periods presented as the impact of all potentially dilutive securities were anti-dilutive. The following potentially dilutive securities were not included in the computation of diluted EPS because to do so would have been anti-dilutive for the periods presented.
		2014			2013
	Warrants		8,332,862			6,508,415
	Common stock options		1,553,906			1,540,402
	Convertible promissory notes		2,541,358			2,387,510
			12,428,126			10,436,327
	Accounting for Common Stock Options
	The Company measures stock-based compensation expense at the grant date, based on the fair value of the award, and recognizes the expense over the employee’s requisite service (vesting) period using the straight-line method. The measurement of stock-based compensation expense is based on several criteria including, but not limited to, the valuation model used and associated input factors, such as expected term of the award, stock price volatility, risk free interest rate and forfeiture rate. Certain of these inputs are subjective to some degree and are determined based in part on management’s judgment. The Company recognizes the compensation expense on a straight-line basis for its graded vesting awards. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. However, the cumulative compensation expense recognized at any point in time must at least equal the portion of the grant-date fair value of the award that is vested at that date. As used in this context, the term “forfeitures” is distinct from “cancellations” or “expirations”, and refers only to the unvested portion of the surrendered equity awards.
	Deferred Rent
	The Company currently leases all of its locations under leases classified as operating leases. Minimum base rent for these operating leases, which generally have escalating rentals over the term of the lease is recorded on a straight-line basis over the lease term. As such, an equal amount of rent expense is attributed to each period during the term of the lease regardless of when actual payments occur. Lease terms begin on the inception date and include option periods only where such renewals are imminent and assured. The difference between rent expense and actual cash payments is classified as “deferred rent” in the accompanying consolidated balance sheets and approximated $288,000 and $252,000 at December 31, 2014 and 2013, respectively.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates include those related to the realization of long-lived assets, deferred income tax asset valuation allowances, and the valuation of equity instruments issued.
	Concentrations
	Financial instruments that subject the Company to credit risk consist primarily of cash and revenues. The Company’s cash and cash equivalents are maintained at financial institutions in the United States. These accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”). At times, such balances may be in excess of the amounts insured by the FDIC. The Company has not experienced any losses on such accounts and believes it is not exposed to any significant credit risks on its cash and cash equivalents.
	A significant portion of the Company’s revenues in 2014 and 2013 were derived from a management services agreement relating to the Company’s California clinics pursuant to a management services agreement with William Kirby D.O., Inc. If the Company’s management services agreement is terminated for any reason or William Kirby, D.O., Inc. defaults on its obligations thereunder, the Company’s operating results, cash flows and financial performance may be adversely affected and the Company may need to negotiate and enter into a new agreement with a qualified physician. Although the Company’s management services agreement provides the Company with the right to approve a replacement contracting physician upon termination or default, the Company can give no assurance that it will be able to expeditiously identify and contract with a qualified replacement physician on commercially reasonable terms or at all. The termination of the Company’s management services arrangement could have a material adverse effect on the Company’s consolidated financial condition, cash flows and results of operations.
	Significant Recent Accounting Pronouncements
	In April 2014, the FASB issued Accounting Standards Update No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360) (“ASU 2014-08”), which changes the requirements for reporting discontinued operations. ASU 2014-08 raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. Under the revised standard, a disposal that represents a strategic shift or will have a major effect on an entity’s operations and financial results will be reported as discontinued operations while smaller disposals will not. ASU 2014-08 is effective in 2015 and interim periods within that year for calendar year companies. Early adoption is permitted and the Company has adopted the new guidance in the first quarter of 2014.  The Company does not expect that this new guidance will have a significant impact on the Company’s consolidated financial position, results of operations or cash flows.
	In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. On April 1, 2015, the FASB voted to propose to defer the effective date of the new revenue recognition standard by one year. The Company is evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures.
	In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40)(“ASU 2014-15”), which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective in the annual period ending after December 15, 2016, with early application permitted. The Company does not expect that this new guidance will have a significant impact on the Company’s consolidated financial position, results of operations or cash flows.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants (“AICPA”), and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3.          PROPERTY AND EQUIPMENT
	Property and equipment, consists of the following at December 31:
		2014			2013
	Equipment	$	1,905,106		$	1,824,871
	Furniture and fixtures		143,893			136,426
	Leasehold improvements		1,452,144			1,217,223
			3,501,143			3,178,520
	Less accumulated depreciation and amortization		(1,516,942	)		(1,128,233	)
		$	1,984,201		$	2,050,287
	Depreciation and amortization expense was approximately $543,000 and $397,000 for the years ended December 31, 2014 and 2013, respectively.
	Assets under capital leases (gross) were approximately $159,000 at December 31, 2014 and 2013. Amortization expense recorded for the assets under capital leases amounted to approximately $0 and $12,000 for the years ended December 31, 2014 and 2013, respectively and is included in the depreciation and amortization amounts noted above. Accumulated amortization of assets under capital leases was approximately $159,000 at December 31, 2014 and December 31, 2013.

REVOLVING_LINE_OF_CREDIT

REVOLVING LINE OF CREDIT	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
REVOLVING LINE OF CREDIT	NOTE 4.          REVOLVING LINE OF CREDIT
	In December 2013, the Company entered into a revolving line of credit with a lender with an initial commitment of $1,300,000 and a maximum revolving commitment of $7,000,000. Increase in the commitment above $1,300,000 is at the sole and absolute discretion of the lender. The term of the revolving loan is for six months subject to two automatic six month extensions as long as the Company is not in default on the credit agreement. In December 2014, the Company entered the final six month extension and the current term of the revolving line of credit expires on June 2, 2015. The line of credit is secured by a second lien on all encumbered equipment of the Company and a first lien on all other assets of the Company.
	The credit agreement requires that all receipts of the Company, except receipts received from investors and receipts from landlords for tenant improvement allowances, be deposited in a lockbox account controlled by the lender. Provided the Company is not in default, it can draw from the lockbox an amount equal to all of the funds deposited in the lockbox less fees and expenses due the lender and a mandatory principal repayment equal to 2% of the funds deposited in the lockbox. The Company deposited $130,000 in the lockbox account as a mandatory principal payment at the time that the loan closed. At December 31, 2014, these funds remain in the lockbox and are unavailable to the Company to draw upon. As a result, the Company recorded a $130,000 reduction in the loan balance. At December 31, 2014, the Company had deposits in the lockbox account of approximately $2,000 available for draw under the revolving line of credit. Cash deposited in the lockbox by the Company in excess of fees and expenses due the lender and the mandatory 2% principal payment are recorded as a further reduction in the loan balance.
	The outstanding principal balance of the loan, which is reduced by funds in the lockbox account, bears interest at 10% per annum and requires a surcharge in the form of a receipts collection fee such that the aggregate interest and receipts collection fee do not exceed 1.5% of the outstanding principal per month. In addition, the Company is obligated to pay an asset monitoring fee of $1,500 per quarter and certain other expenses of the lender. In connection with the initial closing of the revolving line of credit, the Company paid the lender fees for transaction advisory services, due diligence, legal review and related expenses and finder’s fees totaling $136,850 in cash. Additionally, the Company paid a financial advisory firm $26,000 in cash for services in connection with the loan.
	In addition to the cash consideration, the Company issued 125,000 shares of its common stock to the lender. The common stock is subject to a make whole provision such that the value of the common stock issued to the lender is not less than nor can ever be more than $125,000. In August 2014, the Company and the lender entered in to an amendment pursuant to which the Company agreed to repurchase the 125,000 shares of stock at a rate of 10,000 shares per month from August 2014 to May 2015 and 25,000 shares in June 2015. The Company also issued fully vested three-year, callable warrants to three organizations affiliated to the financial advisory firm to purchase up to an aggregate of 39,000 shares of its common stock at an exercise price of $.78 per share in connection with the loan. Loan costs are included in prepaid expenses and were amortized to interest expense over the initial six month term of the loan.
	So long as the revolving note is outstanding, but only upon the occurrence and during the continuance of an event of default, and subject to certain limitations, the lender may convert all or any portion of the amounts due it into common stock of the Company. Beginning with the first quarter of 2014 the Company is subject to a financial covenant which requires that its sales revenue be not less than 75% of its sales revenue for the corresponding quarter of the prior year.

NOTES_PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 5.          NOTES PAYABLE
	Notes payable consist of the following at December 31:
			2014				2013
	Equipment promissory notes		$	533,580			$	674,474
	Tenant improvement secured loans			100,000				100,000
	Unsecured promissory notes			2,163,156				300,000
				2,796,736				1,074,474
	Less unamortized discount			-				(102,487	)
	Less current portion (net of unamortized discounts)			(1,067,530	)			(716,531	)
			$	1,729,206			$	255,456
	Financed Insurance Premiums
	In January 2014, the Company entered into a financing agreement with an unrelated third party to finance the Company’s medical malpractice, property and casualty, and employment liability insurance over a period of nine months.  The note, in the principal amount of $99,265, bore interest at approximately 6.25% per annum, and was repayable in one installment of $8,674 and eight installments of $11,642.  The note matured in September 2014 and is paid in full.
	In March 2014, the Company entered into a financing agreement with an unrelated third party to finance the Company’s directors and officer liability insurance over a period of nine months.  The note, in the principal amount of $46,750, bore interest at approximately 7.68% per annum, and was repayable in nine monthly installments of $5,362.  The note matured in December 2014 and is paid in full.
	Equipment Promissory Notes
	In November 2010, the Company entered into a financing agreement with an unrelated third party to finance computer and telephone equipment to upgrade existing systems and equip its clinic location in Montclair, California.  The note, in the principal amount of $64,157, bears interest at approximately 6% per annum, and is repayable in 60 monthly installments of $1,241.  The note matures in October 2015 and is secured by a first priority purchase money security interest in the equipment.   The balance outstanding on the note was $14,417 and $27,994 at December 31, 2014 and December 31, 2013, respectively.
	In February 2011, the Company entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the location in Montclair, California.  The note, in the principal amount of $118,495, bore interest at approximately 7% per annum, and was repayable in 36 monthly installments of $3,700.  The note matured in January 2014 and was secured by a first priority purchase money security interest in the equipment.  The note was paid off in April 2014. The balance outstanding on the note was $0 and $43,020 at December 31, 2014 and December 31, 2013, respectively.
	In May 2011, the Company entered into a financing agreement with an unrelated third party to finance computer and telephone equipment for its Dallas, Texas clinic and its call center in Irvine, California.  The note, in the principal amount of $17,515, bore interest at approximately 7% per annum, and was repayable in 36 monthly installments of $539.  The note matured in June 2014 and has been paid in full.  The balance outstanding on the note was $0 and $3,171 at December 31, 2014 and December 31, 2013, respectively.
	In June 2011, the Company entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the location in Dallas, Texas.  The note, in the principal amount of $118,495, bore interest at approximately 7% per annum, and was repayable in 36 monthly installments of $3,700.  The note was set to mature in June 2014 and was paid off in April 2014.  The balance outstanding on the note was $0 and $49,390 at December 31, 2014 and December 31, 2013, respectively.
	In June 2012, the Company entered into a financing agreement with an unrelated third party to finance computer and telephone equipment for its Houston, Texas clinic and its clinic planned for Phoenix, Arizona.  The note, in the principal amount of $37,870, bears interest at approximately 6% per annum, and is repayable in 36 monthly installments of $1,148.  The note matures in May 2015 and is secured by a first priority purchase money security interest in the equipment.  The balance outstanding on the note was $5,658 and $18,697 at December 31, 2014 and December 31, 2013, respectively.
	In June 2012, DRTHC I, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the location in Houston, Texas.  The note, in the principal amount of $59,920, bore interest at approximately 7% per annum, and was repayable in 24 monthly installments of $2,683. The note matured in June 2014 and has been paid in full.   The balance outstanding on the note was $0 and $15,773 at December 31, 2014 and December 31, 2013, respectively.
	In November 2012, DRTHC I, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the location in Phoenix, Arizona.  The note, in the principal amount of $67,996, bore interest at approximately 7% per annum, and was repayable in 24 monthly installments of $3,044. The note was scheduled to mature in November 2014 and is secured by a first priority purchase money security interest in the equipment.  Effective September 1, 2014, the parties renegotiated the loan to extend the term to March 2017 and increase the interest rate to 10% per annum.  The new installment amount is $533 per month. The balance outstanding on the note was $12,422 and $32,345 at December 31, 2014 and December 31, 2013, respectively.
	In March 2013, the Company entered into a financing agreement with an unrelated third party to finance telephone equipment for its Sugar Land, Texas clinic (which was subsequently moved to Frisco, Texas) and clinics planned for Fort Worth, Texas and Atlanta, Georgia.  The note, in the principal amount of $34,563 bears interest at approximately 9% per annum, and is repayable in 36 monthly payments of $1,037.  The note matures in March 2016 and is secured by a first priority purchase money security interest in the equipment.    The balance outstanding on the note was $14,401 and $22,538 at December 31, 2014 and December 31, 2013, respectively.
	In March 2013, the Company entered into a financing agreement with an unrelated third party to finance computer equipment for its Sugar Land, Texas clinic which was subsequently moved to Frisco, Texas (a suburb of Dallas) and clinics planned for Fort Worth, Texas and Atlanta, Georgia.  The note, in the principal amount of $37,524, bears interest at approximately 11% per annum, and is repayable in 36 monthly installments of $1,199.  The note matures in February 2016 and is secured by a first priority purchase money security interest in the equipment.   The balance outstanding on the note was $16,746 and $28,590 at December 31, 2014 and December 31, 2013, respectively.
	In March 2013, DRTHC I, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the Sugar Land, Texas clinic (which was subsequently moved to Frisco, Texas).  The note, in the principal amount of $75,920, bore interest at approximately 7% per annum, and was repayable in 24 monthly installments of $3,399.  The note was scheduled to mature in March 2015 and is secured by a first priority purchase money security interest in the equipment.   Effective September 1, 2014, the parties renegotiated the loan to extend the term to March 2017 and increase the interest rate to 10% per annum.  The new installment amount is $1,134 per month. The balance outstanding on the note was $26,407 and $48,485 at December 31, 2014and December 31, 2013, respectively.
	In October 2013, DRTHC II, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of lasers for the Atlanta, Georgia clinic.  The note, in the principal amount of $114,000, bore interest at approximately 7% per annum, and was repayable in 24 monthly installments of $5,104.  The note was scheduled to mature in November 2015 and is secured by a first priority purchase money security interest in the equipment.  Effective September 1, 2014, the parties renegotiated the loan to extend the term to March 2017 and increase the interest rate to 10% per annum.  The new installment amount is $3,151 per month. The balance outstanding on the note was $73,388 and $109,561 at December 31, 2014 and December 31, 2013, respectively.
	In October 2013, DRTHC I, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a hair removal device for the Houston, Texas clinic.  The note, in the principal amount of $28,000, bore interest at approximately 7% per annum, and was repayable in 24 monthly installments of $1,254.  The note was scheduled to mature in November 2015 and is secured by a first priority purchase money security interest in the equipment. Effective September 1, 2014, the parties renegotiated the loan to extend the term to March 2017 and increase the interest rate to 10% per annum.  The new installment amount is $774 per month. The balance outstanding on the note was $18,025 and $26,910 at December 31, 2014 and December 31, 2013, respectively.
	In December 2013, the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of three laser devices for its clinics in Southern California.  The note, in the principal amount of $248,000, bore interest at approximately 7% per annum, and was repayable in 24 monthly installments of $11,104.  The note was scheduled to mature in December 2015 and is secured by a first priority purchase money security interest in the equipment.   Effective September 1, 2014, the parties renegotiated the loan to extend the term to March 2017 and increase the interest rate to 10% per annum.  The new installment amount is $7,238 per month. The balance outstanding on the note was $168,560 and $248,000 at December 31, 2014 and December 31, 2013, respectively.
	In May 2014, the Company, entered into a financing agreement with an unrelated third party manufacturer to finance computer equipment for its Fort Worth, Texas clinic.  The note, in the principal amount of $4,625, bears interest at approximately 13.8% per annum, and is repayable in 36 monthly installments of $157.  The note matures in April 2017 and is secured by a first priority purchase money security interest in the equipment.   The balance outstanding on the note was $3,755 and $0 at December 31, 2014 and December 31, 2013, respectively.
	In June 2014, the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of laser and hair removal devices for the Ft. Worth, Texas and Inland Empire, California clinics.  The note, in the principal amount of $210,000, bore interest at approximately 7% per annum, and was repayable in 24 monthly installments of $9,402.  The note was scheduled to mature in May 2016 and is secured by a first priority purchase money security interest in the equipment.   Effective September 1, 2014, the parties renegotiated the loan to extend the term to March 2017 and increase the interest rate to 10% per annum.  The new installment amount is $7,702 per month. The balance outstanding on the note was $179,800 and $0 at December 31, 2014 and December 31, 2013, respectively.
	All of the equipment promissory notes require the Company to maintain and insure the equipment secured by the note and pay personal property taxes thereon.
	Tenant Improvement Secured Loans
	In February 2013, the Company issued $200,000 in notes, secured by the reimbursements due from landlords with respect to tenant improvements made or to be made by the Company in connection with the development of clinics.  The notes bear interest at 15% and were initially due on August 15, 2013.  As additional consideration for the investors purchasing the notes, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 218,750 shares of the Company’s common stock at an exercise price of $.60 per share.  The fair values of the warrants at the time of issuance, determined by management to be $49,454 in the aggregate, were recorded as a debt discount and were amortized to interest expense over the initial term of the notes.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.60, expected life of five years; risk free interest rate of .08%; volatility of 72% and expected dividend yield of zero.
	In July 2013, in exchange for their agreement to extend the original due date from August 15, 2013 to December 31, 2013, the Company issued five-year fully vested warrants to purchase 220,000 shares of Company common stock at an exercise price of $.60 per share to the note holders. The fair values of the warrants at the time of issuance, determined by management to be $52,500 in the aggregate, were recorded as a debt discount and were amortized to interest expense over the extended term of the notes.
	In December 2013, the Company repaid $100,000 principal amount of its tenant improvement secured loans together with interest due thereon of approximately $15,238 to three note holders, one of whom is an officer of the Company, and entered into extension agreements with respect to the remaining outstanding balance of $100,000. In exchange for an extension of the due date of the notes through March 31, 2014, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 115,240 shares of the Company’s common stock at an exercise price of $.60 per share.  The fair value of the warrants at the time of issuance, determined by management to be approximately $27,700 in the aggregate, was recorded as additional debt discount and amortized to interest expense over the term of the extension.  On April 1, 2014, the Company entered into further extension agreements with respect to the loans. In exchange for an extension of the due date of the notes through September 30, 2014, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 239,353 shares of the Company’s common stock at an exercise price of $.60 per share.  The fair value of the warrants at the time of issuance, determined by management to be $53,200 in the aggregate, was recorded as additional debt discount and was amortized to interest expense over the term of the extension. On October 1, 2014, the Company entered into further extension agreements with respect to the loans, extending the due date to December 31, 2014. The note holders agreed to the extension for no additional consideration. The outstanding balance of the tenant improvement secured loans was $100,000 at December 31, 2014 and December 31, 2013.
	Amortization of the debt discount related to the tenant improvement secured loan was $80,916 for the twelve months ended December 31, 2014 and $101,954 for the year ended December 31, 2013.
	Unsecured Promissory Notes
	In August 2013, the Company issued $120,000 in unsecured promissory notes to three members of its Board of Directors, their families, associates or associated entities.  The notes bear interest at 15% and were initially due on December 31, 2013.  As additional consideration for the investors purchasing the notes, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 120,000 shares of the Company’s common stock at an exercise price of $.60 per share.  The fair values of the warrants at the time of issuance, determined by management to be $22,800 in the aggregate, were recorded as a debt discount and were amortized to interest expense over the initial term of the notes.
	In October 2013, the Company issued $200,000 in unsecured promissory notes to a 5% shareholder.  The note bears interest at 15% and was initially due on December 31, 2013.  As additional consideration for the investor purchasing the note, the Company issued the note holder fully vested five-year warrants to purchase an aggregate of 200,000 shares of the Company’s common stock at an exercise price of $.60 per share.  The fair values of the warrants at the time of issuance, determined by management to be $38,000 in the aggregate, were recorded as a debt discount and were amortized to interest expense over the initial term of the notes.
	In December 2013, the Company repaid $20,000 principal amount of its unsecured promissory notes together with interest due thereon of approximately $1,159 to one note holder, an officer of the Company, and entered into extension agreements with respect to the remaining outstanding balance of unsecured promissory notes of $300,000. In exchange for an extension of the due date of the notes through March 31, 2014, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 310,893 shares of the Company’s common stock at an exercise price of $.60 per share.  The fair value of the warrants at the time of issuance, determined by management to be $74,771 in the aggregate, was recorded as additional debt discount and was amortized to interest expense over the term of the extension.  In exchange for a further extension of the due date of the notes through September 30, 2014, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 643,973 shares of the Company’s common stock at an exercise price of $.60 per share.  The fair value of the warrants at the time of issuance, determined by management to be $143,000 in the aggregate, was recorded as additional debt discount and was amortized to interest expense over the term of the extension.  On October 1, 2014, the Company entered into further extension agreements with respect to the loans, extending the due date to December 31, 2014. The note holders agreed to the extension for no additional consideration. In 2015, the maturity date of the notes was extended to January 1, 2016. Amortization of the debt discount related to the 2013 unsecured promissory notes and their extensions was $217,771 for the year ended December 31, 2014 and $60,800 for the year ended December 31, 2013.
	In February, March, and April, 2014 the Company issued $950,000 of short-term unsecured promissory notes. The short-term unsecured promissory notes were issued to Board members and their affiliates, and certain parties who are already lenders or investors in the Company. The purpose of the offering was to provide immediate funds to support the opening of new clinics in Frisco and Ft. Worth, Texas and additional marketing while the Company works to complete a convertible debt offering. The notes matured on April 30, 2014, and bore interest at 15% per annum, and were planned to be repaid from the proceeds of a $2 million convertible debt offering.  As additional consideration for the lenders, the Company agreed to issue equity to the lenders depending upon the date of repayment of the loan. In June 2014, the Company issued an additional $100,000 of the short-term unsecured promissory notes under similar terms, with the maturity and other target dates adjusted to reflect the later date of issuance. During 2014, the Company issued 2,000,000 shares of its common stock to the note holders as the payments became due. The Company recorded expense related to the issued shares at an estimated fair value of $0.40-$0.49 per share, which was charged to interest expense and costs of financing in the accompanying consolidated statements of operations. In December 2014, the Company entered into an amendment with all of the holders of these short-term unsecured promissory notes. Pursuant to the amendment, the holders agreed to extend the due date of the loan and extended the dates upon which interest to be paid in shares of Company common stock or as repayment premium would be due.  Pursuant to the amended terms, the maturity date has been extended to January 1, 2016 when all principal and interest, including interest in the form of common stock, will be due. The Company also redeemed the 2,000,000 shares that had previously been issued to the holders. The Company recorded the redemption at an estimated fair value of $0.33 per share. The note holders earned four shares of common stock and a repayment premium equal to 100% of the principal amount on March 31, 2015 as the notes remained unpaid on that date. In the event that the notes are not repaid on the maturity date, the holders will be entitled to an additional one-quarter of one share of common stock and repayment premium equal to 10% for each dollar loaned to the Company.
	At December 31, 2014 the balance of the these notes included in the accompanying consolidated balance sheets was approximately $3,119,000. The balance consists of the present value of the principal, of 4,200,000 shares of common stock at an estimated fair value of $0.33 per share, and of the repayment premium earned as of March 31, 2015. The discount from face value of approximately $639,000 will be charged to interest expense and costs of financing over the year remaining to maturity.
	The short-term unsecured promissory notes remain unpaid as of the date hereof.
	From July to December 2014, the Company issued $813,156 in additional short-term notes to an officer and two significant shareholders. The notes are included in notes payable, current portion (net of unamortized discount) in the accompanying consolidated balance sheets. The notes bear interest at 15% per annum and are due on demand.
	The following table sets forth the future maturities of the Company’s outstanding notes payable, net of unamortized discount:
		Year ended
		December 31,
	2015				$	1,067,530
	2016					1,688,001
	2017					41,205
	Total				$	2,796,736

CONVERTIBLE_PROMISSORY_NOTES

CONVERTIBLE PROMISSORY NOTES	12 Months Ended
	Dec. 31, 2014
Convertible Promissory Notes [Abstract]
CONVERTIBLE PROMISSORY NOTES	NOTE 6.          CONVERTIBLE PROMISSORY NOTES
	Convertible promissory notes payable consist of the following at December 31:
		2014			2013
	Secured senior subordinated convertible promissory notes	$	892,500		$	892,500
	Senior subordinated convertible promissory notes		685,000			585,000
			1,577,500			1,477,500
	Less unamortized discount		(36,949	)		(201,125	)
	Less current portion (net of unamortized discounts)		(373,051	)		(947,987	)
		$	1,167,500		$	328,388
	Secured Senior Subordinated Convertible Promissory Notes
	Between May 2012 and January 2013, the Company issued $892,500 of secured senior subordinated convertible promissory notes, respectively to two members of the Company’s Board of Directors, their associates or associated entities, and others.  The notes are convertible at the option of the holder at any time during the term of the note into common stock of the Company at an initial conversion price of $.60 per share, subject to adjustment for stock splits or subdivisions.  The notes bear interest at 12% per annum, which interest is payable quarterly, and are due at maturity.  The notes matured in May 2014 or mature December 2015 (with respect to the $300,000 of notes issued in January 2013) and are secured by a first priority lien on the ownership interest of the Company in its wholly-owned subsidiary DRTHC I, LLC or DRTHC II, LLC (with respect to the notes issued in January 2013). The balance outstanding on the notes was $892,500 at December 31, 2014 and December 31, 2013. As additional consideration for the investors purchasing the notes, the Company issued the note holders five-year warrants to purchase an aggregate of 1,115,625 shares of the Company’s common stock at an exercise price of $.75 per share. The fair values of the warrants at the time of issuance, determined by management to be $217,225 in the aggregate, were recorded as a debt discount and amortized to interest expense over the initial term of the notes. The notes also contained a beneficial conversion feature determined by management to be $45,066 in the aggregate which was recorded as a debt discount which was amortized to interest expense over the initial term of the notes. In May 2014, the Company entered into agreements with holders of $492,500 of the notes to extend the term to December 31, 2014. The Company issued the extending holders five year fully vested warrants to purchase 985,000 shares of common stock at a purchase price of $.60 per share. The fair value of the warrants at the time of issuance, determined by management to be $217,500 in the aggregate, was recorded as a debt discount and was amortized to interest expense over the term of the extension. Amortization of the debt discount was $283,273 for the year ended December 31, 2014 and $129,282 for the year ended December 31, 2013. In 2015, the holders of $792,500 in principal amount of notes agreed to extend the maturity date to January 1, 2016. One holder of $100,000 in notes refused to extend the due date. The Company is working with the note holder on a plan of repayment.
	Senior Subordinated Convertible Promissory Notes
	Between May 2013 and July 2013, the Company issued $485,000 of senior subordinated convertible promissory notes to two members of the Company’s Board of Directors, two 5% shareholders, and others.  The notes are convertible at the option of the holder at any time during the term of the note into common stock of the Company at an initial conversion price of $.65 per share, subject to adjustment for stock splits or subdivisions.  The notes are mandatorily convertible in the event of a Qualified Transaction (as defined in the notes) and the conversion price is adjustable to the lower of 75% of the price of a share of common stock sold in the Qualified Transaction or $.65. The notes bear interest at 7% per annum, are payable upon conversion or at maturity.  The notes matured November 1, 2014 and are unsecured. In 2015, holders of $450,000 in principal amount of the notes agreed to extend the maturity date to January 1, 2016. The Company is seeking an extension with respect to the remaining notes. As additional consideration for the investors purchasing the notes, the Company issued the note holders fully vested three-year warrants to purchase an aggregate of 746,157 shares of the Company’s common stock at an exercise price equal to the lower of 120% of the conversion price or $.78 per share. The balance outstanding on the notes was $485,000 at December 31, 2014 and December 31, 2013. The fair values of the warrants at the time of issuance, determined by management to be $92,283 in the aggregate, were recorded as a debt discount and was amortized to interest expense over the initial term of the notes. Amortization of the debt discount was $91,408 for the year ended December 31, 2014 and $875 for the year ended December 31, 2013.
	Between September 2013 and January 2014, the Company issued $125,000 of senior subordinated convertible promissory notes to investors.  The notes are convertible at the option of the holder at any time during the term of the note into common stock of the Company at an initial conversion price of $.65 per share, subject to adjustment for stock splits or subdivisions.  The notes are mandatorily convertible in the event of a Qualified Transaction (as defined in the notes) and the conversion price is adjustable to the lower of 75% of the price of a share of common stock sold in the Qualified Transaction or $.65. The notes bear interest at 7% per annum, payable upon conversion or at maturity.  The notes matured in March 2015 and are unsecured. As additional consideration for the investor purchasing the notes, the Company issued the note holders fully vested three-year warrants to purchase an aggregate of 192,308 shares of the Company’s common stock at an exercise price equal to the lower of 120% of the conversion price or $.78 per share. The balance outstanding on the notes was $125,000 at December 31, 2014 and $100,000 at December 31, 2013, respectively. The fair values of the warrants at the time of issuance, determined by management to be approximately $22,000 in the aggregate, were recorded as a debt discount and will be amortized to interest expense over the initial term of the notes.  Amortization of the debt discount was $16,409 for the year ended December 31, 2014 and $1,721 for the year ended December 31, 2013. The Company is seeking an extension of the maturity date from the holders.
	In June 2014, the Company issued $75,000 of senior subordinated convertible promissory notes.  The notes are convertible at the option of the holder at any time during the term of the note into common stock of the Company at an initial conversion price of $.65 per share, subject to adjustment for stock splits or subdivisions.  The notes are mandatorily convertible in the event of a Qualified Transaction (as defined in the notes) and the conversion price is adjustable to the lower of 75% of the price of a share of common stock sold in the Qualified Transaction or $.65. The notes bear interest at 7% per annum, payable upon conversion or at maturity.  The notes mature in November 2015 and are unsecured. As additional consideration for the investor purchasing the notes, the Company issued the note holders fully vested three-year warrants to purchase an aggregate of 115,386 shares of the Company’s common stock at an exercise price equal to the lower of 120% of the conversion price or $.78 per share. The balance outstanding on the notes was $75,000 at December 31, 2014 and $0 at December 31, 2013. The fair values of the warrants at the time of issuance, determined by management to be approximately $9,600 in the aggregate, were recorded as a debt discount and will be amortized to interest expense over the term of the notes.   Amortization of the debt discount was $4,200 for the year ended December 31, 2014 and $0 for the year ended December 31, 2013.
	The following table sets forth the future maturities of the Company’s convertible promissory notes net of unamortized discount at December 31, 2014:
	Year ended
	December 31,
	2015	$	373,051
	2016		1,167,500
	Total	$	1,540,551

CAPITAL_LEASE_OBLIGATIONS_RELA

CAPITAL LEASE OBLIGATIONS (RELATED PARTY)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
CAPITAL LEASE OBLIGATIONS (RELATED PARTY)	NOTE 7.         CAPITAL LEASE OBLIGATIONS (RELATED PARTY)
	Capital lease obligations (related party) consisted of the following at December 31:
		2014			2013
	$199,610 capital lease obligation on equipment. The lease bears interest at 9.65%, is payable monthly in principal and interest installments of $2,704 and matures in May 2018.	$	43,630		$	53,916
	Total capital lease obligations		43,630			53,916
	Less current portion		(11,323	)		(10,286	)
	Long-term portion	$	32,307		$	43,630
	The future minimum capital lease payments are as follows for the years ending December 31:
	2015	$	15,041
	2016		15,041
	2017		15,041
	2018		6,267
	Total minimum lease payments		51,390
	Less amount representing interest		(7,760	)
	Present value of minimum lease payments		43,630
	Less current portion		(11,323	)
	Long-term portion	$	32,307

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 8.          RELATED PARTY TRANSACTIONS
	Management Services Agreement
	The Company and William Kirby D.O., Inc. operate under a management agreement entered into effective January 1, 2010, whereby the Company provides technical, management, administrative, marketing, support services and equipment to the sites where William Kirby D.O., Inc. provides or supervises tattoo removal services. The agreement covers four clinics in southern California operated by the Company. The Company had a $0 receivable due from William Kirby D.O., Inc. at December 31, 2014 and December 31, 2013.
	Pursuant to the Management Services Agreement, the Company provides certain non-medical management, administrative, marketing and support services to the clinics where William Kirby, D.O., Inc. provides or supervises laser tattoo and hair removal services, which such services include employment of all non-licensed administrative personnel including an on-site manager and receptionist for each site and all support personnel such as accounting, information technology, human resources, purchasing and maintenance. The Company also provides certain supplies, furniture and equipment used at the clinics. The Company is also responsible for identifying and leasing the clinic locations and paying all rent, utilities and maintenance costs related thereto. Under the Management Services Agreement, the Company also arranges third party marketing and advertising for the clinics.
	Medical Director Agreement
	Effective January 1, 2010, the Company entered into a Medical Director Agreement with William Kirby, D.O., Inc. and Dr. Kirby, under which the Company receives administrative, consultative and strategic services from William Kirby, D.O. The initial term of the agreement was for five years and it expired effective as of December 31, 2014. The agreement provided for an annual payment of $250,000 to William Kirby, D.O. for these services. The Company’s unpaid current obligation under the Medical Director Agreement was $20,833 and $0 at December 31, 2014 and 2013, respectively. The unpaid amounts are included in related party payables in the accompanying consolidated balance sheets.
	Lease Arrangements
	The IPL device currently used in one of the Company’s clinics is owned by William Kirby, D.O., Inc. pursuant to a financing agreement with a third party financing source.  In addition, under the Management Services Agreement, the Company has the right, at any time, to purchase the equipment from William Kirby, D.O., Inc. at a purchase price of the amount outstanding, if any, under the applicable financing agreement.  The Company has accounted for this as a capital lease based on the agreement terms.
	Shareholders Agreement
	Effective January 1, 2010, the Company entered into a Shareholders Agreement with William Kirby, D.O., Inc. and Dr. Kirby, pursuant to which, upon the occurrence of certain triggering events described below, Dr. Kirby is required to transfer his interest in William Kirby, D.O., Inc. to another licensed person or entity approved by the Company. Such triggering events include but are not limited to (i) the death or incapacity of Dr. Kirby, (ii) the loss of Dr. Kirby’s medical license, (iii) a breach of the obligations of William Kirby, D.O., Inc. and/or Dr. Kirby under the Amended and Restated Management Services Agreement or the Medical Director Agreement, (iv) the voluntary or involuntary transfer of Dr. Kirby’s interest in William Kirby, D.O., Inc., or (v) termination of the Amended and Restated Management Services Agreement in certain circumstances.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
EQUITY	NOTE 9.          EQUITY
	Common Stock
	In January 2013, the Company issued 35,700 shares of common stock to an employee pursuant to the exercise of a non-qualified stock option. The Company received gross proceeds of approximately $17,500 in connection with the option exercise. In March 2013, the Company sold 136,365 shares of common stock in a private placement for aggregate gross proceeds of approximately $75,000 and issued 423,061 shares of common stock valued at $.49 per share in exchange for services provided to the Company including an aggregate of 270,000 shares of common stock issued to the Company’s three independent directors as compensation for serving in such capacity and 153,061 shares issued to a consultant in connection with brand development.
	In April 2013, the Company sold 90,910 shares of common stock in a private placement for aggregate gross proceeds of approximately $50,000. In May 2013, the Company issued 145,455 shares of common stock valued at $.49 per share in exchange for consulting services provided to the Company.
	In December 2013, the Company issued 13,636 shares of common stock valued at $.49 per share in exchange for consulting services provided to the Company and issued 125,000 shares of common stock to a lender in connection with a line of credit. Also in December 2013, the Company issued 5,300 shares of its common stock to non-executive employees as additional compensation.
	In February through June, the Company entered into a series of short-term unsecured promissory notes pursuant to which the note holders would be entitled to equity in the form of warrants or common stock as of certain dates in the event that the note remained unpaid. Holders of the notes earned 475,000 shares of common stock in the second quarter of 2014 and 525,000 shares of common stock in the third quarter of 2014 and 1,000,000 shares of common stock in the fourth quarter or 2014.  In December 2014, the Company entered into an amendment with all of the holders of its short-term unsecured promissory notes. Pursuant to the amendment, the holders agreed to extend the due date of the loan and extended the dates upon which interest to be paid in shares of Company common stock or as repayment premium would be due.  Pursuant to the amended terms, the maturity date has been extended to January 1, 2016 when all principal and interest, including interest in the form of common stock, will be due. The Company also redeemed the 2,000,000 shares that had previously been issued to the holders. The note holders earned four shares of common stock and a repayment premium equal to 100% of the principal amount on March 31, 2015 as the notes remained unpaid on that date. In the event that the notes are not repaid on the maturity date, the holders will be entitled to an additional one-quarter of one share of common stock and repayment premium equal to 10% for each dollar loaned to the Company.
	In July 2014, the Company issued 10,500 shares of common stock valued at $.49 per share to a vendor in exchange for a reduction in fees.
	In each month from August through December 2014, the Company repurchased 10,000 shares of common stock from a lender at a purchase price of $.49 per share as required pursuant to an amendment in the credit agreement.  The Company accounted for the repurchase of shares using the constructive retirement method as the Company’s state of incorporation does not recognize treasury shares.
	Stock Options
	In April 2011, the Company’s board of directors adopted the Dr. Tattoff, Inc. Long-Term Incentive Plan for the purpose of granting incentive awards, including equity awards such as stock options or restricted stock, to certain officers, employees, directors, consultants and other service providers of our Company, to provide such recipients with additional incentives to enhance the value of our Company and encourage stock ownership. Under the Long-Term Incentive Plan, we can grant incentive and nonqualified options to purchase shares of our common stock, stock appreciation rights, other stock-based awards, which are settled in either cash or shares of our common stock and are determined by reference to shares of our stock (such as grants of restricted common stock, grants of rights to receive stock in the future or dividend equivalent rights) and cash performance awards, which are settled in cash and are not determined by reference to shares of our common stock.
	In January 2013, the Company granted 61,225 incentive stock options to an executive officer as part of his compensation package, vesting over twelve months with an exercise price of $.49.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock option approximated $17,300 on its issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.67%; volatility of 73%; and expected dividend yield of zero.
	In March 2013, the Company granted 24,041 incentive options to executive officers, 13,264 incentive options to other employees of the Company and 6,517 non-qualified options to employees of William Kirby, D.O., Inc., vesting immediately with an exercise price of $.49 as consideration for their agreement to defer compensation.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $14,000 on their issuance date.   Also in March 2013, the Company granted 20,000 non-qualified options to each of the three independent members of its Board of Directors, vesting immediately and 45,000 options to each of the three independent members of its Board of Directors vesting 50% immediately and 25% on each the first and second anniversary of the grant date, with an exercise price of $.49 per share as compensation for serving on the Company’s Board of Directors.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $52,000 on their issuance date.  Also in March 2013, the Company granted 10,000 non-qualified options to each of five members of its medical advisory board, with 25% vesting immediately and 25% vesting on each of the first, second and third anniversary of the grant date with an exercise price of $.49 per share.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $13,400 on their issuance date.  Also in March 2013, the Company granted 10,000 non-qualified options to each of five members of its medical advisory board, vesting 25% on each of the first through fourth anniversary of the grant date with an exercise price of $.55 per share.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $13,400 on their issuance date.  All of the estimates of the values of the options granted during March 2013 were based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.63%; volatility of 73%; and expected dividend yield of zero.
	In June 2013, the Company granted 212,413 incentive stock options to an employee as part of his compensation package, vesting over a four year period with an exercise price of $.55.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock option approximated $53,200 on its issuance date.  Also, in June 2013, the Company granted 10,000 non-qualified options to a new member of its medical advisory board, vesting 25% on each of the first through fourth anniversary of the grant date with an exercise price of $.55 per share.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $2,503 on their issuance date.  All of the estimates of the values of the options granted during June 2013 were based on the following assumptions: value of one common share of $0.49; strike price of $0.55, expected life of five years; risk-free interest rate of 1.07%; volatility of 64%; and expected dividend yield of zero.
	In July 2013, the Company granted 112,727 incentive options to two executive officers as part of their compensation packages, vesting over a four year period with an exercise price of $.55. As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $28,100 on the issuance date. Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.55, expected life of five years; risk-free interest rate of 1.42%; volatility of 63%; and expected dividend yield of zero.
	In October 2013, the Company granted 7,327 incentive options to executive officers, 2,513 incentive options to other employees of the Company and 6,088 non-qualified options to William Kirby, D.O., vesting immediately with an exercise price of $.55 as consideration for their agreement to defer compensation.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $3,900 on their issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.55; expected life of five years; risk-free interest rate of 1.41%; volatility of 63%; and expected dividend yield of zero.
	In February 2014, the Company granted 54,545 incentive stock options to an executive officer as part of his compensation package vesting over twelve months with an exercise price of $.55.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock option approximated $13,200 on its issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.55; expected life of five years; risk-free interest rate of 1.57%; volatility of 61%; and expected dividend yield of zero.
	The Company recognized compensation expense of approximately $69,000 in the year ended December 31, 2014 and $136,000 for the year ended December 31, 2013 related to the options and grants, which is included in general and administrative expenses in the accompanying consolidated statements of operations.
	The following table summarizes stock option activity for the year ended December 31, 2014:
										Weighted
										Average
							Weighted			Grant-Date
			Number				Average Exercise			Fair Value
			of Options				Price per Share			per Share
	Outstanding at December 31, 2013			1,549,230			$	0.45		$	0.44
	Granted			54,545				0.55			0.49
	Exercised			-				-			-
	Forfeited or Expired			(49,869	)			0.39			0.39
	Outstanding at December 31, 2014			1,553,906			$	0.46		$	0.44
	Exercisable at December 31, 2014			1,119,679			$	0.45		$	0.43
	Vested and expected to vest at December 31, 2014			1,553,906			$	0.46		$	0.44
	The aggregate intrinsic value of options exercised during the twelve months ended December 31, 2014 was $0. The aggregate intrinsic value of outstanding options was approximately $21,000 at December 31, 2014.
	Warrants
	The Company issued a number of warrants in 2013 and 2014 related to various transactions.  In each case, the Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model.  During 2013, the Company used the following assumptions: value of common share of $.49, expected life of three or five years depending on the term of the warrant; risk free interest rate of between .58% and 1.73%; volatility of 63-72% and expected dividend yield of zero.  During 2014, the Company used the following assumptions: value of common share of $.49, expected life of three or five years depending on the term of the warrant; risk free interest rate of between .86% and 1.73%; volatility between 46% and 61% and expected dividend yield of zero.  Unless indicated otherwise, the Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In January 2013, the Company issued five-year warrants to purchase 30,613 shares of the Company’s common stock at a purchase price of $.595 per share to an employee as part of his compensation package.  The warrants vested on a monthly basis through January 1, 2014.   The estimated fair value at issuance of $8,200 was recognized as “compensation expense” and is included within “general and administrative” expenses on the consolidated statements of operations.
	In connection with issuance of the secured senior subordinated convertible notes in a private placement in January 2013, the Company issued fully vested five-year warrants to purchase 375,000 shares of the Company’s common stock at a purchase price of $.75 per share as additional consideration to the investors, including 250,000 warrant shares to two members of the Company’s Board of Directors.   The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $89,500 and the convertible notes issued in the offering.
	In connection with issuance and subsequent extension of the maturity date of the tenant improvement secured loan initially made in February 2013, the Company issued fully vested five-year warrants to purchase 585,240 shares of the Company’s common stock at a purchase price of $.60 per share as additional consideration to the investors, including 146,310 warrant shares to members of the Company’s Board of Directors and management.   The net proceeds on the issuance of the tenant improvement secured loan were allocated between the estimated fair value of the warrants at issuance of approximately $145,900 and the notes issued in the offering.
	In March 2013, the Company issued fully vested five-year warrants to purchase 76,530 shares of the Company’s common stock at a purchase price of $.595 per share to a service provider as additional consideration for services provided.  The warrant expires on January 15, 2018.  The estimated fair value at issuance of $20,500 was recognized as “consulting expense” and is included within “general and administrative” expenses on the consolidated statements of operations.
	In connection with the sale of common stock in a private placement in March and April 2013, the Company issued fully vested five-year warrants to purchase 170,457 shares of the Company’s common stock at a purchase price of $.65 per share as additional consideration to the investors.   The net proceeds on the sale of common stock were allocated between the estimated fair value of the warrants at issuance of $41,600 and the common stock sold in the offering.
	In May 2013, the Company issued five-year warrants, vesting over one year, to purchase 34,090 shares of the Company’s common stock at a purchase price of $.65 per share to a service provider as additional consideration for services provided.   The estimated fair value at issuance of approximately $7,800 was recognized as “consulting expense” and is included within “general and administrative” expenses on the consolidated statements of operations.
	In connection with issuance of the senior subordinated convertible notes in a private placement in May, June and July 2013, the Company issued fully vested five-year warrants to purchase 186,537 shares of the Company’s common stock at a purchase price of $.78 per share as additional consideration to the investors.  The warrants were exchanged in December 2013 for warrants with different terms as described below.
	In connection with the issuance and subsequent extension of the maturity date of unsecured promissory notes originally issued in August and October 2013, the Company issued five-year warrants to purchase 630,893 shares of the Company’s common stock at a purchase price of $.60 per share as additional consideration to the note holders, including 97,174 shares issued to members of the Company’s Board of Directors and management. The net proceeds on the unsecured promissory notes were allocated between the estimated fair value of the warrants at issuance of approximately $141,500 and the notes issued.
	In July 2013, the Company issued five-year warrants to purchase 84,545 shares of the Company’s common stock at a purchase price of $.65 per share to two employees as part of their compensation package.  The warrants vest on a monthly basis through July 2014 at which time the warrant will be fully vested.  The estimated fair value at issuance of $19,400 was recognized as “compensation expense” and is included within “general and administrative” expenses on the consolidated statements of operations.
	In connection with the issuance of senior subordinated convertible notes in a private placement from September 2013 to January 2014, the Company issued fully vested three-year warrants to purchase 153,846 shares of the Company’s common stock at a purchase price of $.78 per share as additional consideration to the investors.  In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 100% of the number of conversion shares and the strike price adjusted to 120% of the conversion price. The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of approximately $25,800 and the convertible notes issued in the offering.  The Company has analyzed these warrants and determined them to be debt instruments.  Accordingly, the estimated fair value of the warrants was recognized as “warrant liability” on the consolidated balance sheets. The Company determined the fair value of the warrant liability to be approximately $4,100 at December 31, 2014.
	In October 2013 the Company issued fully vested five-year warrants to purchase 450,000 shares of the Company’s common stock at a purchase price of $1.00 per share in exchange for consulting services to be delivered over a twelve month period. The estimated fair value of the warrants at issuance of $80,300 was recognized as consulting expense included in general and administrative expense on the consolidated statements of operations. Of these warrants, 225,000 were cancelled in February 2014.
	In December 2013 the Company issued fully vested three-year warrants to purchase 39,000 shares of the Company’s common stock at a purchase price of $.78 per share in exchange for services related to the Company’s new revolving loan facility. The Company has analyzed these warrants and determined them to be debt instruments. Accordingly, the estimated fair value of the warrants was recognized as “warrant liability” on the consolidated balance sheets and the expense will be amortized over the term of the revolving loan and included in interest expense. The Company determined the fair value of the warrant liability to be $4,300 at issuance and $900 at December 31, 2014.
	In December 2013, the Company exchanged 186,537 warrants that had been issued in connection with the issuance of the senior subordinated convertible notes in a private placement from May to July 2013 with new warrants. The number of shares of common stock that can be purchased by the warrant holder was increased to 746,157 and the term of the warrant was decreased from five to three years. In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 100% of the number of conversion shares and the strike price adjusted to 120% of the conversion price. The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $91,400 and the convertible notes issued in the offering.  The Company has analyzed these warrants and determined them to be debt instruments.  Accordingly, the estimated fair value of the warrants was recognized as “warrant liability” on the consolidated balance sheets. The Company determined the fair value of the warrant liability to be approximately $13,100 and $91,400 at December 31, 2014 and December 31, 2013, respectively.
	In February 2014, the Company issued five-year warrants to purchase 27,273 shares of the Company’s common stock at a purchase price of $.65 per share to an employee as part of his compensation package.  The warrants vested on a monthly basis through January 1, 2015.   The estimated fair value at issuance of $6,100 was recognized as “compensation expense” and is included within “general and administrative” expenses on the consolidated statements of operations.
	In April 2014, the Company issued the holders of $100,000 of its Tenant Improvement Secured Loans five year fully vested warrants to purchase 239,353 shares of the Company’s common stock at a purchase price of $.60 per share in exchange for their agreement to extend the due date to December 31, 2014. The fair value of the warrants at the time of issuance, determined by management to be $53,200 in the aggregate, was recorded as a debt discount and amortized to interest expense over the term of the extension.
	In April 2014, the Company issued the holders of $300,000 of its unsecured promissory notes five year fully vested warrants to purchase 643,973 shares of the Company’s common stock at a purchase price of $.60 per share in exchange for their agreement to extend the due date to September 30, 2014. The fair value of the warrants at the time of issuance, determined by management to be $143,000 in the aggregate, was recorded as a debt discount and amortized to interest expense over the term of the extension.
	In May 2014, the Company issued the holders of $492,500 of its Secured Senior Subordinated Convertible Promissory Notes five year fully vested warrants to purchase 985,000 shares of the Company’s common stock at a purchase price of $.60 per share in exchange for their agreement to extend the due date to December 31, 2014. The fair value of the warrants at the time of issuance, determined by management to be $217,500 in the aggregate, was recorded as a debt discount and amortized to interest expense over the term of the extension.
	In connection with the issuance of senior subordinated convertible notes in a private placement in June 2014, the Company issued fully vested three-year warrants to purchase 115,386 shares of the Company’s common stock at a purchase price of $.78 per share as additional consideration to the investors.  In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 100% of the number of conversion shares and the strike price adjusted to 120% of the conversion price. The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of approximately $9,600 and the convertible notes issued in the offering.  The Company has analyzed these warrants and determined them to be debt instruments.  Accordingly, the estimated fair value of the warrants was recognized as “warrant liability” on the consolidated balance sheets. The Company determined the fair value of the warrant liability to be approximately $6,200 at December 31, 2014.
	The following tables summarize the warrant activity:
							Weighted
							Average			Weighted Average
							Exercise			Remaining Contractual
			Shares				Price			Life (in years)
	Outstanding at January 1, 2013			3,150,434			$	0.64			4.5
	Granted			3,562,914				0.73			4
	Exercised			-				-			-
	Expired or cancelled			(204,933	)			0.93			-
	Exercisable at December 31, 2013			6,508,415			$	0.62			3.8
	Granted			2,049,447				0.61			4.7
	Exercised			-				-			-
	Expired or cancelled			(225,000	)			1			-
Exercisable at December 31, 2014			8,332,862			$	0.65			3.1
Warrants Outstanding and Exercisable
											Weighted
					Range of						Average
	Number of Shares				Exercise			Expiration			Exercise
	Under Warrants				Prices			Date			Price
	128,840				$	0.37			2015		$	0.37
	915,651					.59-.78			2016			0.77
	3,103,481					.49-.78			2017			0.63
	2,289,291					.60-1.00			2018			0.68
	1,895,599					.60-.65			2019			0.6
	8,332,862				$	.37-1.00					$	0.65

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10. COMMITMENTS AND CONTINGENCIES
	Legal Contingencies
	From time to time, the Company is involved in legal matters which arise in the normal course of business. Management believes that the final resolution of such matters will not have a material adverse effect on the Company’s financial position or results of operations.
	Operating Leases
	The Company leases al of its clinics from unrelated third parties, which expire through 2020. Lease agreements, in addition to base rentals, generally are subject to annual escalation provisions that range from 3% to 4% and options to renew ranging from 3 years to 5 years.
	The aggregate minimum future payments required on the operating leases are as follows for the years ending December 31:
	2015	$	625,613
	2016		574,981
	2017		464,847
	2018		193,741
	2019		99,631
	Thereafter		52,480
		$	2,011,293
	Rent expense relating to related party leases for the years ended December 31, 2014 and December 31, 2013 approximated $11,000 and $42,000, respectively. Rent expense related to third party leases for the years ended December 31, 2014 and December 31, 2013 approximated $639,000 and $586,000, respectively.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11. INCOME TAXES
	The Company accounts for income taxes under the provisions of ASC 740, which requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns.
	The components of the provision for income taxes for the years ended December 31, 2014 and 2013 is comprised of the following:
		2014			2013
	Current
	Federal	$	-		$	-
	State		3,863			800
			3,863			800
	Deferred
	Federal		-			-
	State		-			-
	Total	$	3,863		$	800
	The difference between income taxes at statutory rates and the amount presented in the consolidated financial statements is a result of the following for the years ended December 31, 2014 and 2013:
		2014			2013
	Computed expected income tax benefit at federal statutory rates		34	%		34	%
	Addition to (reduction in) income taxes resulting from:
	State income taxes, net of federal benefit		6	%		6	%
	Other		-	%		-	%
	Valuation allowance		(40	%)		(40	%)
	Total		0	%		0	%
	Deferred taxes arise because of temporary differences in the book and tax bases of certain assets and liabilities. Significant components of deferred taxes at December 31, 2014 and 2013 are set forth below:
		2014			2013
	Net operating loss carryforwards	$	5,900,000		$	4,286,000
	Other		1,668,000			708,000
	Less valuation allowance		(7,568,000	)		(4,994,000	)
	Net deferred tax assets	$	–		$	–
	The Company has federal tax net operating loss carryforwards of approximately $13,200,000 and $9,200,000, at December 31, 2014 and December 31, 2013, respectively, both of which will begin expiring in 2030. The Company has California state tax net operating loss carryforwards of approximately $10,900,000 and $6,900,000, at December 31, 2014 and December 31, 2013, respectively, which will begin expiring in 2029. The amount of net operating loss carry forward that can be used in any one year may be limited by significant changes in ownership as defined by section 382 of the Internal Revenue Code and similar state tax laws.
	In assessing the realizability of deferred tax assets, management considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based upon the Company’s history of continuing operating losses, realization of its deferred tax assets does not meet the “more likely than not” criteria under ASC 740. Accordingly, the Company has recorded a 100% valuation allowance to offset the net deferred tax assets at December 31, 2014 and 2013. For the years ended December 31, 2014 and 2013, the Company’s change in valuation allowance was approximately $2,570,000 and $1,635,000, respectively.
	The Company will recognize interest and penalties related to unrecognized tax benefits and penalties as income tax expense. As of December 31, 2014, the Company has not recognized liabilities for penalties and interest as the Company does not have liabilities for unrecognized tax benefits. The Company’s income tax returns are subject to examination by the taxing authorities, generally three years for federal and four years for state (California).

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12. SUBSEQUENT EVENTS
	Subsequent events have been evaluated through the date on which these financial statements have been issued.
	In March 2015, the Company and holders of its various debt instruments agreed to amend the terms of the agreements to extend the due date of both principal and interest until January 1, 2016. Holders agreeing to the amendment will exchange any warrants that they hold with respect to the debt instrument for shares of fully paid, non- assessable common stock of the Company at an exchange rate of 0.4 shares of common stock for each warrant share exchanged. Holders representing $100,000 of the Company’s secured tenant improvement loans, $1,350,000 of its unsecured notes, and $1,167,500 of its convertible notes have entered into such amendment.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying consolidated financial statements of Dr. Tattoff, Inc. and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid short-term investments with original maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company adopted the fair value measurement and disclosure requirements of ASC 820, Fair Value Measurements and Disclosure for financial assets and liabilities measured on a recurring basis. ASC 820 defines fair value, establishes a framework for measuring fair value under GAAP and expands disclosures about fair value measurements. This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820 does not require any new fair value measurements.
	Fair value is defined in ASC 820 as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The standard describes three levels of inputs that may be used to measure fair value:
	Level 1:             Quoted prices in active markets for identical or similar assets and liabilities.
	Level 2:             Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
	Level 3:             Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial instruments include cash and cash equivalents, prepaid expenses and other current assets, other assets, accounts payable, related party payable, accrued expenses and other liabilities, deferred revenue, accrued compensation, capital lease obligations, convertible promissory notes, notes payable, and warrant liabilities.  The carrying amounts of prepaid expenses and other current assets, other assets, accounts payable, related party payable, accrued expenses and other liabilities, deferred revenue and accrued compensation approximate their fair values due to the short maturity of these instruments.  The carrying amounts of capital leases, convertible promissory notes, and notes payable approximates their fair value as these instruments earn or are charged interest based on prevailing rates. The fair value of warrants is measured using level 3 inputs.
Long-lived Assets	Long-lived Assets
	Long-lived assets are reviewed for impairment in accordance with ASC No. 360 “Accounting for the Impairment or Disposal of Long-Lived Assets,” which requires impairment losses to be recorded on long-lived assets when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of the impairment review, assets are reviewed on an asset-by-asset basis. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of each asset to future net cash flows on an undiscounted basis expected to be generated by such asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount which the carrying amount of the assets on an undiscounted basis exceeds the fair value of the assets.
	The major long-lived assets of the Company are the lasers and Intense Pulse Light, or IPL, devices. While the Company has sustained losses, the clinics where the lasers and IPL devices are located are or are expected to be profitable. As a result, recoverability of assets to be held and used is measured by a comparison of the carrying amount of each asset to future net cash flows on an undiscounted basis expected to be generated by such asset in each clinic. There were no impairments of long-lived assets at December 31, 2013. In February 2014, the Company decided to close its Sugar Land, Texas (a suburb of Houston) clinic due to poor financial performance. The Company concluded that the capitalized tenant improvements were impaired and recorded an impairment charge of approximately $40,000 related to the closure. The impairment charge is included in clinic operating expenses in the accompanying consolidated statements of operations. The Company moved the laser and other capital assets located there to other clinics. In February 2015, the Company entered into a mutual release and settlement agreement with the landlord pursuant to which the Company agreed to make payments totaling $87,000 over a period of two years to the landlord. There have been no other impairments in 2014.
Property and Equipment	Property and Equipment
	Property and equipment is recorded at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets. The Company uses the following estimated useful lives for computing depreciation expense: furniture and fixtures, 7 years; medical equipment, 7 years; other equipment, 3 to 5 years. Amortization of leasehold improvements is recorded using the straight-line method based on the lesser of the useful life of the improvement or the lease term, which is typically five years or less.
Debt and Other Financial Instruments	Debt and Other Financial Instruments
	Debt/Equity Instruments Issued with Warrants
	The Company estimates the relative fair values of the debt and warrants, and allocates the proceeds pro-rata based on these values. The allocation of proceeds to the warrants results in the debt instrument being recorded at a discount from the face amount of the debt and the value allocated to the warrant is recorded to additional paid-in capital.
	The Company reviews the terms of convertible financial instruments it issues to determine whether there are embedded derivative instruments, including the conversion option that may be required to be bifurcated and accounted for separately as a derivative financial instrument. In circumstances where the convertible instrument contains more than one embedded derivative, including the conversion option that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	When the convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds from the convertible host instruments are first allocated to the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, resulting in those instruments being recorded at a discount from their face value.
	Derivative Financial Instruments
	Derivative instruments are initially recorded at estimated fair value and are then revalued at each reporting date with changes in the estimated fair value reported as charges or credits to income.
Revenue Recognition	Revenue Recognition
	Currently, the majority of the Company’s revenues are derived from management services provided to William Kirby D.O., Inc., a related party, for our non-owned clinics. The Company provides nonmedical services and facilities based on contractual prices established in advance that extend continuously over a set time for a fixed percentage of the contracting physician’s gross revenues (as defined in the Management Services Agreement - See Note 8, “Related Party Transactions”) with no upfront fees paid by William Kirby D.O., Inc. The management services agreement with William Kirby D.O., Inc. covers all of the Company’s California locations.
	Under the management service agreement with William Kirby D.O., Inc., there is no right to refund or rejection of services. The Company recognizes revenue when the following criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Management services fees are paid by the contracting physician to the Company on a bi-weekly basis as earned, which is when the Company has substantially performed management services pursuant to the terms of the management services agreement with William Kirby D.O., Inc.
	The Company operates the Dallas, Houston, Atlanta and Phoenix locations directly, not pursuant to a management services agreement with a physician. Accordingly, patients contract with the Company and pay for the services they receive directly to the Company. The Company recognizes revenue when the following criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. The Company requires payment at the time of the patient visit or in advance of the visit by those patients purchasing packages of treatments. Payments by patients made in advance of service delivery are recorded as “deferred revenue” on the accompanying consolidated balance sheets and amounted to approximately $1,529,000 at December 31, 2014 and $1,114,000 at December 31, 2013.
	Patients who purchase a package of tattoo removal services at clinics the Company operates directly are eligible to participate in the Company’s tattoo removal guarantee program. Pursuant to the guarantee program, if the tattoo is not fully removed within the recommended number of treatments, the Company will continue to provide additional treatments, consistent with the Company’s medical protocols, for a period of up to one year following the date of the last paid treatment. The Company estimates the cost of the guarantee program based on historical usage and the average cost of treatments. The cost of the program is accrued on a per visit basis as visits occur and is included in clinic operating expense on the accompanying consolidated statements of operations. The Company recognized accrued expense of approximately $132,000 and $77,000 as of December 31, 2014 and December 31, 2013, respectively, related to the guarantee program, and this is included in the accrued expenses and other liabilities in the accompanying consolidated balance sheets. Patients who purchase a package of services and experience complete removal prior to completion of the package are eligible for a refund for the unused portion of the package. The Company recognizes refunds, which have been immaterial in amount, as a reduction in revenue as incurred. Patients who receive services in clinics operated under the management services agreement with William Kirby, D.O., Inc. are eligible for similar programs, which may reduce the management fee that the Company receives.
Advertising Costs	Advertising Costs
	Advertising costs are expensed as incurred. For the years ended December 31, 2014 and 2013, advertising expense was approximately $465,000 and $570,000, respectively, and is included in marketing and advertising in the accompanying consolidated statement of operations.
Income Taxes	Income Taxes
	The Company accounts for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740 “Income taxes.” Under ASC 740, deferred income taxes are recognized to reflect the tax consequences in future years for the differences between the amounts of assets and liabilities recognized for financial reporting purposes and such amounts recognized for income tax reporting purposes using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce net deferred tax assets to amounts that are more likely than not to be realized.
	The Company has incurred tax net operating losses since inception and, accordingly, has a deferred tax asset related to such tax net operating loss carryforwards. The Company has provided a 100% valuation allowance on such deferred tax asset at December 31, 2014 and 2013 (See Note 11, “Income Taxes”).
	The Company accounts for uncertainty in income taxes in accordance with ASC 740-10, which prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740-10 also provides guidance on the measurement, derecognition, classification and disclosure of tax positions, as well as the accounting for related interest and penalties. The Company’s policy is to recognize interest and penalties that would be assessed in relation to the settlement value of unrecognized tax benefits as a component of income tax expense. The Company has recognized no tax related interest or penalties since the adoption of ASC 740-10. As of December 31, 2014, the open tax years of the Company were 2009 to 2014.
Earnings Per Share	Earnings Per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. In computing diluted earnings per share, the treasury stock method assumes that outstanding options are exercised and the proceeds are used to purchase common stock at the average market price during the period. Options will have a dilutive effect under the treasury stock method only when the Company reports net income and the average market price of the common stock during the period exceeds the exercise price of the options. Options, warrants and conversions of convertible debt instruments were not included in computing diluted earnings per share for the years ended December 31, 2014 and 2013, respectively because their effects were antidilutive.
	The following table illustrates the computation of basic and diluted earnings per share:
		2014			2013
	Net loss available to common stockholders (numerator)	$	(6,589,936	)	$	(4,300,543	)
	Weighted average shares outstanding (denominator)		20,106,722			18,743,738
	Basic and diluted EPS	$	(.33	)	$	(.23	)
	Basic and diluted EPS are the same for all periods presented as the impact of all potentially dilutive securities were anti-dilutive. The following potentially dilutive securities were not included in the computation of diluted EPS because to do so would have been anti-dilutive for the periods presented.
		2014			2013
	Warrants		8,332,862			6,508,415
	Common stock options		1,553,906			1,540,402
	Convertible promissory notes		2,541,358			2,387,510
			12,428,126			10,436,327
Accounting for Common Stock Options	Accounting for Common Stock Options
	The Company measures stock-based compensation expense at the grant date, based on the fair value of the award, and recognizes the expense over the employee’s requisite service (vesting) period using the straight-line method. The measurement of stock-based compensation expense is based on several criteria including, but not limited to, the valuation model used and associated input factors, such as expected term of the award, stock price volatility, risk free interest rate and forfeiture rate. Certain of these inputs are subjective to some degree and are determined based in part on management’s judgment. The Company recognizes the compensation expense on a straight-line basis for its graded vesting awards. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. However, the cumulative compensation expense recognized at any point in time must at least equal the portion of the grant-date fair value of the award that is vested at that date. As used in this context, the term “forfeitures” is distinct from “cancellations” or “expirations”, and refers only to the unvested portion of the surrendered equity awards.
Deferred Rent	Deferred Rent
	The Company currently leases all of its locations under leases classified as operating leases. Minimum base rent for these operating leases, which generally have escalating rentals over the term of the lease is recorded on a straight-line basis over the lease term. As such, an equal amount of rent expense is attributed to each period during the term of the lease regardless of when actual payments occur. Lease terms begin on the inception date and include option periods only where such renewals are imminent and assured. The difference between rent expense and actual cash payments is classified as “deferred rent” in the accompanying consolidated balance sheets and approximated $288,000 and $252,000 at December 31, 2014 and 2013, respectively.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates include those related to the realization of long-lived assets, deferred income tax asset valuation allowances, and the valuation of equity instruments issued.
Concentrations	Concentrations
	Financial instruments that subject the Company to credit risk consist primarily of cash and revenues. The Company’s cash and cash equivalents are maintained at financial institutions in the United States. These accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”). At times, such balances may be in excess of the amounts insured by the FDIC. The Company has not experienced any losses on such accounts and believes it is not exposed to any significant credit risks on its cash and cash equivalents.
	A significant portion of the Company’s revenues in 2014 and 2013 were derived from a management services agreement relating to the Company’s California clinics pursuant to a management services agreement with William Kirby D.O., Inc. If the Company’s management services agreement is terminated for any reason or William Kirby, D.O., Inc. defaults on its obligations thereunder, the Company’s operating results, cash flows and financial performance may be adversely affected and the Company may need to negotiate and enter into a new agreement with a qualified physician. Although the Company’s management services agreement provides the Company with the right to approve a replacement contracting physician upon termination or default, the Company can give no assurance that it will be able to expeditiously identify and contract with a qualified replacement physician on commercially reasonable terms or at all. The termination of the Company’s management services arrangement could have a material adverse effect on the Company’s consolidated financial condition, cash flows and results of operations.
Significant Recent Accounting Pronouncements	Significant Recent Accounting Pronouncements
	In April 2014, the FASB issued Accounting Standards Update No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360) (“ASU 2014-08”), which changes the requirements for reporting discontinued operations. ASU 2014-08 raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. Under the revised standard, a disposal that represents a strategic shift or will have a major effect on an entity’s operations and financial results will be reported as discontinued operations while smaller disposals will not. ASU 2014-08 is effective in 2015 and interim periods within that year for calendar year companies. Early adoption is permitted and the Company has adopted the new guidance in the first quarter of 2014.  The Company does not expect that this new guidance will have a significant impact on the Company’s consolidated financial position, results of operations or cash flows.
	In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. On April 1, 2015, the FASB voted to propose to defer the effective date of the new revenue recognition standard by one year. The Company is evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures.
	In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40)(“ASU 2014-15”), which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective in the annual period ending after December 15, 2016, with early application permitted. The Company does not expect that this new guidance will have a significant impact on the Company’s consolidated financial position, results of operations or cash flows.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants (“AICPA”), and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

ORGANIZATION_AND_NATURE_OF_OPE1

ORGANIZATION AND NATURE OF OPERATIONS (Tables)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Schedule of carrying amount and classification of assets and liabilities
		December 31,
		2014		2013
	Current Liabilities
	Related party payables	$	290,567	$	23,622
	Capital lease obligations, current portion		11,323		10,286
	Long-Term Liabilities
	Capital lease obligations, net of current portion		32,307		43,630

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of computation of basic and diluted earnings per share
		2014			2013
	Net loss available to common stockholders (numerator)	$	(6,589,936	)	$	(4,300,543	)
	Weighted average shares outstanding (denominator)		20,106,722			18,743,738
	Basic and diluted EPS	$	(.33	)	$	(.23	)
Schedule of dilutive securities excluded from the computation of diluted EPS
		2014			2013
	Warrants		8,332,862			6,508,415
	Common stock options		1,553,906			1,540,402
	Convertible promissory notes		2,541,358			2,387,510
			12,428,126			10,436,327

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of property and equipment
		2014			2013
	Equipment	$	1,905,106		$	1,824,871
	Furniture and fixtures		143,893			136,426
	Leasehold improvements		1,452,144			1,217,223
			3,501,143			3,178,520
	Less accumulated depreciation and amortization		(1,516,942	)		(1,128,233	)
		$	1,984,201		$	2,050,287

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Schedule of components of notes payable			2014				2013
	Equipment promissory notes		$	533,580			$	674,474
	Tenant improvement secured loans			100,000				100,000
	Unsecured promissory notes			2,163,156				300,000
				2,796,736				1,074,474
	Less unamortized discount			-				(102,487	)
	Less current portion (net of unamortized discounts)			(1,067,530	)			(716,531	)
			$	1,729,206			$	255,456
Schedule of future maturities of the company's outstanding notes payable		Year ended
		December 31,
	2015				$	1,067,530
	2016					1,688,001
	2017					41,205
	Total				$	2,796,736

CONVERTIBLE_PROMISSORY_NOTES_T

CONVERTIBLE PROMISSORY NOTES (Tables)	12 Months Ended
	Dec. 31, 2014
Convertible Promissory Notes [Abstract]
Schedule of convertible promissory notes payable		2014			2013
	Secured senior subordinated convertible promissory notes	$	892,500		$	892,500
	Senior subordinated convertible promissory notes		685,000			585,000
			1,577,500			1,477,500
	Less unamortized discount		(36,949	)		(201,125	)
	Less current portion (net of unamortized discounts)		(373,051	)		(947,987	)
		$	1,167,500		$	328,388
Schedule of future maturities of the Company's outstanding convertible promissory notes	Year ended
	December 31,
	2015	$	373,051
	2016		1,167,500
	Total	$	1,540,551

CAPITAL_LEASE_OBLIGATIONS_RELA1

CAPITAL LEASE OBLIGATIONS (RELATED PARTY) (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Schedule of components of capital lease obligations		2014			2013
	$199,610 capital lease obligation on equipment. The lease bears interest at 9.65%, is payable monthly in principal and interest installments of $2,704 and matures in May 2018.	$	43,630		$	53,916
	Total capital lease obligations		43,630			53,916
	Less current portion		(11,323	)		(10,286	)
	Long-term portion	$	32,307		$	43,630
Schedule of future minimum capital lease payments	2015	$	15,041
	2016		15,041
	2017		15,041
	2018		6,267
	Total minimum lease payments		51,390
	Less amount representing interest		(7,760	)
	Present value of minimum lease payments		43,630
	Less current portion		(11,323	)
	Long-term portion	$	32,307

EQUITY_Tables

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Schedule of company's stock option activity										Weighted
										Average
							Weighted			Grant-Date
			Number				Average Exercise			Fair Value
			of Options				Price per Share			per Share
	Outstanding at December 31, 2013			1,549,230			$	0.45		$	0.44
	Granted			54,545				0.55			0.49
	Exercised			-				-			-
	Forfeited or Expired			(49,869	)			0.39			0.39
	Outstanding at December 31, 2014			1,553,906			$	0.46		$	0.44
	Exercisable at December 31, 2014			1,119,679			$	0.45		$	0.43
	Vested and expected to vest at December 31, 2014			1,553,906			$	0.46		$	0.44
Schedule of company's warrant activity							Weighted
							Average			Weighted Average
							Exercise			Remaining Contractual
			Shares				Price			Life (in years)
	Outstanding at January 1, 2013			3,150,434			$	0.64			4.5
	Granted			3,562,914				0.73			4
	Exercised			-				-			-
	Expired or cancelled			(204,933	)			0.93			-
	Exercisable at December 31, 2013			6,508,415			$	0.62			3.8
	Granted			2,049,447				0.61			4.7
	Exercised			-				-			-
	Expired or cancelled			(225,000	)			1			-
	Exercisable at December 31, 2014			8,332,862			$	0.65			3.1
Schedule of stockholders equity warrants or rights outstanding and exercisable	Warrants Outstanding and Exercisable
												Weighted
						Range of						Average
		Number of Shares				Exercise			Expiration			Exercise
		Under Warrants				Prices			Date			Price
		128,840				$	0.37			2015		$	0.37
		915,651					.59-.78			2016			0.77
		3,103,481					.49-.78			2017			0.63
		2,289,291					.60-1.00			2018			0.68
		1,895,599					.60-.65			2019			0.6
		8,332,862				$	.37-1.00					$	0.65

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of aggregate minimum future payments required on the operating leases	2015	$	625,613
	2016		574,981
	2017		464,847
	2018		193,741
	2019		99,631
	Thereafter		52,480
		$	2,011,293

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of components for provision for income taxes		2014			2013
	Current
	Federal	$	-		$	-
	State		3,863			800
			3,863			800
	Deferred
	Federal		-			-
	State		-			-
	Total	$	3,863		$	800
Schedule of income taxes reconciliation at statutory rates		2014			2013
	Computed expected income tax benefit at federal statutory rates		34	%		34	%
	Addition to (reduction in) income taxes resulting from:
	State income taxes, net of federal benefit		6	%		6	%
	Other		-	%		-	%
	Valuation allowance		(40	%)		(40	%)
	Total		0	%		0	%
Schedule of components for deferred taxes		2014			2013
	Net operating loss carryforwards	$	5,900,000		$	4,286,000
	Other		1,668,000			708,000
	Less valuation allowance		(7,568,000	)		(4,994,000	)
	Net deferred tax assets	$	–		$	–

ORGANIZATION_AND_NATURE_OF_OPE2

ORGANIZATION AND NATURE OF OPERATIONS - Summary of carrying amount and classification of assets and liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Liabilities
Related party payables	$290,567	$23,622
Capital lease obligations, current portion	11,323	10,286
Long-Term Liabilities
Capital lease obligations, net of current portion	32,307	43,630
William Kirby, D.O., Inc
Current Liabilities
Related party payables	290,567	23,622
Capital lease obligations, current portion	11,323	10,286
Long-Term Liabilities
Capital lease obligations, net of current portion	$32,307	$43,630

ORGANIZATION_AND_NATURE_OF_OPE3

ORGANIZATION AND NATURE OF OPERATIONS (Detail Textuals) (USD $)	1 Months Ended	12 Months Ended
	Feb. 29, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2012	Feb. 28, 2011
		Entity
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Increased number of authorized share capital						28,571,429
Increase in number of common stock		75,000,000	75,000,000		75,000,000	25,714,286
Common stock, par value (in dollars per share)		$0.00	$0.00			$0.00
Increase in number of preferred stock		2,857,143	2,857,143			2,857,143
Reverse stock split ratio	7-for-1
Accumulated losses		($18,297,836)	($11,707,900)
Working capital surplus (deficit)		-6,487,000
Shareholders' deficit		($9,861,126)	($4,012,991)	($806,078)
Number of entities		2

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of computation of basic and diluted earnings per share (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Net loss available to common stockholders (numerator)	($6,589,936)	($4,300,543)
Weighted average shares outstanding (denominator) (in shares)	20,106,722	18,743,738
Basic and diluted EPS (in dollars per share)	($0.33)	($0.23)

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of dilutive securities which were not included in computation of diluted EPS (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted EPS	12,428,126	10,436,327
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted EPS	8,332,862	6,508,415
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted EPS	1,553,906	1,540,402
Convertible promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted EPS	2,541,358	2,387,510

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation methods of property and equipment	straight-line method
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful lives for computing depreciation expense	7 years
Medical equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives for computing depreciation expense	7 years
Other equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives for computing depreciation expense	3 to 5 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives for computing depreciation expense	five years or less

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals 1) (USD $)	12 Months Ended		2 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Feb. 28, 2015
Summary Of Significant Accounting Policies [Line Items]
Impairment charge	$40,000
Accrued expense	132,000	77,000
Advertising expense	465,000	570,000
Deferred rent	287,852	251,597
Subsequent Event
Summary Of Significant Accounting Policies [Line Items]
Payments for rent over a period of two years			$87,000

PROPERTY_AND_EQUIPMENT_Summary

PROPERTY AND EQUIPMENT - Summary of components of property and equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$3,501,143	$3,178,520
Less accumulated depreciation and amortization	-1,516,942	-1,128,233
Property and equipment, net	1,984,201	2,050,287
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,905,106	1,824,871
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	143,893	136,426
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$1,452,144	$1,217,223

PROPERTY_AND_EQUIPMENT_Detail_

PROPERTY AND EQUIPMENT (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$542,695	$397,413

PROPERTY_AND_EQUIPMENT_Detail_1

PROPERTY AND EQUIPMENT (Detail Textuals 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Accumulated amortization	$1,516,942	$1,128,233
Assets under capital leases
Property, Plant and Equipment [Line Items]
Assets under capital leases (gross)	159,000	159,000
Amortization expense	0	12,000
Accumulated amortization	$159,000	$159,000

REVOLVING_LINE_OF_CREDIT_Detai

REVOLVING LINE OF CREDIT (Detail Textuals) (Revolving Credit Facility, USD $)	1 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Revolving Credit Facility
Line of Credit Facility [Line Items]
Initial commitment for revolving line of credit	$1,300,000
Maximum revolving commitment	7,000,000
Term of revolving loan	6 months
Line of credit facility, description	The term of the revolving loan is for six months subject to two automatic six month extensions as long as the Company is not in default on the credit agreement.
Increase in initial commitments at discretion of lender	1,300,000
Percentage of funds deposited in lockbox for repayment of mandatory principal		2.00%
Amount of mandatory principal payment deposited in lockbox account		130,000
Amount of reduction in loan balance		130,000
Funds deposited in lockbox		$2,000

REVOLVING_LINE_OF_CREDIT_Detai1

REVOLVING LINE OF CREDIT (Detail Textuals 1) (Revolving Credit Facility, USD $)	12 Months Ended	1 Months Ended		10 Months Ended
	Dec. 31, 2014	Aug. 31, 2014	Jun. 30, 2015	31-May-15
	Organization
Line of Credit Facility [Line Items]
Interest rate for outstanding principal balance of the loan	10.00%
Line of credit facility, interest rate description	The outstanding principal balance of the loan, which is reduced by funds in the lockbox account, bears interest at 10% per annum and requires a surcharge in the form of a receipts collection fee such that the aggregate interest and receipts collection fee do not exceed 1.5% of the outstanding principal per month.
Maximum percentage of outstanding principal	1.50%
Asset monitoring fee per quarter	$1,500
Lender fees and related expenses	136,850
Cash paid for services in connection with loan	26,000
Description of common stock issued to lender	Value of the common stock issued to the lender is not less than nor can ever be more than $125,000.
Vesting period specified for callable warrants	3 years
Number of organizations affiliated to financial advisory firm	3
Sales
Line of Credit Facility [Line Items]
Minimum percentage of sales revenue	75.00%
Common Stock
Line of Credit Facility [Line Items]
Number of shares issued to lender	125,000
Threshold limit specified for value of common stock issued to lender	$125,000
Number of common stock called by warrants	39,000
Exercise price of warrants	$0.78
Common Stock | Credit agreement | First Amendment
Line of Credit Facility [Line Items]
Number of redemption shares issued to lender		125,000
Common Stock | Credit agreement | First Amendment | Subsequent Event
Line of Credit Facility [Line Items]
Number of redemption shares per month			25,000	10,000

NOTES_PAYABLE_Summary_of_compo

NOTES PAYABLE - Summary of components of notes payable (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Less current portion (net of unamortized discounts)	$1,067,530	$716,531
Notes payable, net	1,729,206	255,456
Notes payable
Debt Instrument [Line Items]
Total, notes payable	2,796,736	1,074,474
Less unamortized discount		-102,487
Less current portion (net of unamortized discounts)	-1,067,530	-716,531
Notes payable, net	1,729,206	255,456
Notes payable | Equipment promissory notes
Debt Instrument [Line Items]
Total, notes payable	533,580	674,474
Notes payable | Tenant improvement secured loans
Debt Instrument [Line Items]
Total, notes payable	100,000	100,000
Notes payable | Unsecured promissory notes
Debt Instrument [Line Items]
Total, notes payable	$2,163,156	$300,000

NOTES_PAYABLE_Summary_of_futur

NOTES PAYABLE - Summary of future maturities of outstanding notes payable (Details 1) (Notes payable, USD $)	Dec. 31, 2014
Notes payable
Debt Instrument [Line Items]
2015	$1,067,530
2016	1,688,001
2017	41,205
Total	$2,796,736

NOTES_PAYABLE_Detail_Textuals

NOTES PAYABLE (Detail Textuals) (Notes payable, USD $)	1 Months Ended
	Jan. 31, 2014	Mar. 31, 2014
	Installment	Installment
Financed Insurance Premiums at 6.25% Matures In September 2014 | Medical Malpractice Property And Casualty And Employment Liability Insurance Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount	$99,265
Debt instrument, interest rate	6.25%
Term of agreement	9 months
Number of monthly installments for repayment of debt	1
Debt instrument, monthly installment	8,674
Number of monthly installments for repayment of debt two	8
Debt instrument, monthly installment two	11,642
Financed Insurance Premiums at 7.68% Matures In December 2014 | Directors and Officer Liability Insurance Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount		46,750
Debt instrument, interest rate		7.68%
Term of agreement		9 months
Number of monthly installments for repayment of debt		9
Debt instrument, monthly installment		$5,362

NOTES_PAYABLE_Detail_Textuals_

NOTES PAYABLE (Detail Textuals 1) (Notes payable, USD $)	1 Months Ended
	Nov. 30, 2010	Feb. 28, 2011	31-May-11	Jun. 30, 2011	Jun. 30, 2012	Sep. 30, 2014	Nov. 30, 2012	Mar. 31, 2013	Oct. 31, 2013	Dec. 31, 2013	31-May-14	Jun. 30, 2014	Dec. 31, 2014
	Installment	Installment	Installment	Installment	Installment		Installment	Installment	Installment	Installment	Installment	Installment
Debt Instrument [Line Items]
Balance outstanding										$1,074,474			$2,796,736
Non convertible promissory notes at 6% matures in October 2015 | Computer and Telephone Equipment Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount	64,157
Debt instrument, interest rate	6.00%
Number of monthly installments for repayment of debt	60
Debt instrument, monthly installment	1,241
Balance outstanding										27,994			14,417
Non convertible promissory notes at 7% matures in January 2014 | Purchase of Laser Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount		118,495
Debt instrument, interest rate		7.00%
Number of monthly installments for repayment of debt		36
Debt instrument, monthly installment		3,700
Balance outstanding										43,020			0
Non convertible promissory notes at 7% matures in June 2014 | Computer and Telephone Equipment Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount			17,515
Debt instrument, interest rate			7.00%
Number of monthly installments for repayment of debt			36
Debt instrument, monthly installment			539
Balance outstanding										3,171			0
Non convertible promissory notes at 7% matures in June 2014 | Purchase of Laser Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount				118,495
Debt instrument, interest rate				7.00%
Number of monthly installments for repayment of debt				36
Debt instrument, monthly installment				3,700
Balance outstanding										49,390			0
Non convertible promissory notes at 7% matures in June 2014 | DRTHC I, LLC | Purchase of Laser Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount					59,920
Debt instrument, interest rate					7.00%
Number of monthly installments for repayment of debt					24
Debt instrument, monthly installment					2,683
Balance outstanding										15,773			0
Non convertible promissory notes at 6% matures in May 2015 | Computer and Telephone Equipment Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount					37,870
Debt instrument, interest rate					6.00%
Number of monthly installments for repayment of debt					36
Debt instrument, monthly installment					1,148
Balance outstanding										18,697			5,658
Non convertible promissory notes at 7% matures in November 2014 | DRTHC I, LLC | Purchase of Laser Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount							67,996
Debt instrument, interest rate						10.00%	7.00%
Number of monthly installments for repayment of debt							24
Debt instrument, monthly installment						533	3,044
Balance outstanding										32,345			12,422
Non convertible promissory notes at 9% matures in March 2016 | Computer and Telephone Equipment Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount								34,563
Debt instrument, interest rate								9.00%
Number of monthly installments for repayment of debt								36
Debt instrument, monthly installment								1,037
Balance outstanding										22,538			14,401
Non convertible promissory notes at 11% matures in February 2016 | Computer and Telephone Equipment Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount								37,524
Debt instrument, interest rate								11.00%
Number of monthly installments for repayment of debt								36
Debt instrument, monthly installment								1,199
Balance outstanding										28,590			16,746
Non convertible promissory notes at 7% matures in March 2015 | DRTHC I, LLC | Purchase of Laser Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount								75,920
Debt instrument, interest rate						10.00%		7.00%
Number of monthly installments for repayment of debt								24
Debt instrument, monthly installment						1,134		3,399
Balance outstanding										48,485			26,407
Non convertible promissory notes at 7% matures in November 2015 | DRTHC I, LLC | Purchase of Hair Removal Device Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount									28,000
Debt instrument, interest rate						10.00%			7.00%
Number of monthly installments for repayment of debt									24
Debt instrument, monthly installment						774			1,254
Balance outstanding										26,910			18,025
Non convertible promissory notes at 7% matures in November 2015 | DRTHC II, LLC | Purchase of Laser Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount									114,000
Debt instrument, interest rate						10.00%			7.00%
Number of monthly installments for repayment of debt									24
Debt instrument, monthly installment						3,151			5,104
Balance outstanding										109,561			73,388
Non convertible promissory notes at 7% matures in December 2015 | Purchase of Laser Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount										248,000
Debt instrument, interest rate						10.00%				7.00%
Number of monthly installments for repayment of debt										24
Debt instrument, monthly installment						7,238				11,104
Balance outstanding										248,000			168,560
Non convertible promissory notes at 13.8% matures in April 2017 | Computer and Telephone Equipment Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount											4,625
Debt instrument, interest rate											13.80%
Number of monthly installments for repayment of debt											36
Debt instrument, monthly installment											157
Balance outstanding										0			3,755
Non convertible promissory notes at 7% matures in May 2016 | Purchase of Hair Removal Device Financing Agreement
Debt Instrument [Line Items]
Debt instrument, principal amount												210,000
Debt instrument, interest rate						10.00%						7.00%
Number of monthly installments for repayment of debt												24
Debt instrument, monthly installment						7,702						9,402
Balance outstanding										$0			$179,800

NOTES_PAYABLE_Detail_Textuals_1

NOTES PAYABLE (Detail Textuals 2) (USD $)	12 Months Ended		3 Months Ended	1 Months Ended									6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Apr. 30, 2014	Dec. 31, 2013	Feb. 28, 2013	Jul. 31, 2013	Jun. 30, 2014	Aug. 31, 2013	Oct. 31, 2013	Mar. 31, 2014	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2012
					Note_Holder				Member				Note_Holder
Debt Instrument [Line Items]
Proceeds of convertible debt offering used to repay notes payable	$100,000	$885,000
Interest paid	282,961	135,972
Amortization of the debt discount	693,975	308,633
Common Stock
Debt Instrument [Line Items]
Number of redemption shares issued to lender			2,000,000
Estimated fair value redemption stock	$0.33		$0.33										$0.33
Warrants
Debt Instrument [Line Items]
Exercise price of warrants	$0.65	$0.62	$0.65		$0.62								$0.65	$0.64
Value of common share (in dollars per share)	$0.49	$0.49	$0.49		$0.49								$0.49
Expected dividend yield	0.00%	0.00%
Warrants | Minimum
Debt Instrument [Line Items]
Expected life	3 years	3 years
Risk free interest rate	0.86%	0.58%
Volatility rate	46.00%	63.00%
Warrants | Maximum
Debt Instrument [Line Items]
Expected life	5 years	5 years
Risk free interest rate	1.73%	1.73%
Volatility rate	61.00%	72.00%
Tenant improvement secured loans
Debt Instrument [Line Items]
Secured senior convertible promissory note issued				100,000
Tenant improvement secured loans | Warrants
Debt Instrument [Line Items]
Number of common stock called by warrants				239,353		585,240
Exercise price of warrants				$0.60		$0.60
Fair values of warrants				53,200		145,900
Expected life				5 years
Notes payable
Debt Instrument [Line Items]
Balance outstanding	2,796,736	1,074,474	2,796,736		1,074,474								2,796,736
Discount from face value charged to interest expense and costs of financing	639,000		639,000										639,000
Notes payable | Tenant improvement secured loans
Debt Instrument [Line Items]
Secured senior convertible promissory note issued						200,000
Debt instrument, interest rate						15.00%
Principal amount paid					100,000
Interest paid					15,238
Balance outstanding	100,000	100,000	100,000		100,000								100,000
Amortization of the debt discount	80,916	101,954
Number of note holders					3
Notes payable | Tenant improvement secured loans | Warrants
Debt Instrument [Line Items]
Number of common stock called by warrants		115,240		239,353	115,240	218,750	220,000
Exercise price of warrants		$0.60		$0.60	$0.60	$0.60	$0.60
Fair values of warrants		27,700		53,200	27,700	49,454	52,500
Value of common share (in dollars per share)						$0.49
Strike price						$0.60
Expected life				5 years	5 years	5 years	5 years
Risk free interest rate						0.08%
Volatility rate						72.00%
Expected dividend yield						0.00%
Notes payable | Unsecured promissory notes of $100,000
Debt Instrument [Line Items]
Secured senior convertible promissory note issued								100,000
Notes payable | Unsecured promissory notes of $120,000
Debt Instrument [Line Items]
Secured senior convertible promissory note issued									120,000
Debt instrument, interest rate									15.00%
Number of members									3
Notes payable | Unsecured promissory notes of $120,000 | Warrants
Debt Instrument [Line Items]
Number of common stock called by warrants									120,000
Exercise price of warrants									$0.60
Fair values of warrants									22,800
Expected life									5 years
Notes payable | Unsecured promissory notes of $200,000
Debt Instrument [Line Items]
Secured senior convertible promissory note issued										200,000
Debt instrument, interest rate										15.00%
Percentage of shareholder										5.00%
Notes payable | Unsecured promissory notes of $200,000 | Warrants
Debt Instrument [Line Items]
Number of common stock called by warrants										200,000
Exercise price of warrants										$0.60
Fair values of warrants										38,000
Expected life										5 years
Notes payable | Unsecured promissory notes of $20,000
Debt Instrument [Line Items]
Principal amount paid					20,000
Interest paid					1,159
Balance outstanding		300,000			300,000
Amortization of the debt discount	217,771	60,800
Notes payable | Unsecured promissory notes of $20,000 | Warrants
Debt Instrument [Line Items]
Number of common stock called by warrants		310,893			310,893
Exercise price of warrants		$0.60			$0.60
Fair values of warrants		74,771			74,771
Expected life					5 years
Notes payable | Unsecured promissory notes of $950,000
Debt Instrument [Line Items]
Secured senior convertible promissory note issued				950,000							950,000	950,000
Proceeds of convertible debt offering used to repay notes payable	2,000,000
Debt instrument, interest rate				15.00%							15.00%	15.00%
Common stock issue to note holders	2,000,000
Notes payable | Unsecured promissory notes of $950,000 | Minimum
Debt Instrument [Line Items]
Estimated fair value	$0.40		$0.40										$0.40
Notes payable | Unsecured promissory notes of $950,000 | Maximum
Debt Instrument [Line Items]
Estimated fair value	$0.49		$0.49										$0.49
Notes payable | Unsecured promissory notes of $950,000 | Repaid on March 31, 2015
Debt Instrument [Line Items]
Repayment premium as a percentage	100.00%
Number of shares received in lieu of warrants	4		4										4
Notes payable | Unsecured promissory notes of $950,000 | Repaid Thereafter
Debt Instrument [Line Items]
Repayment premium as a percentage	10.00%
Number of shares received in lieu of warrants	0.33		0.33										0.33
Notes payable | Unsecured promissory notes of 20,000 due in September, 2014 | Warrants
Debt Instrument [Line Items]
Number of common stock called by warrants		643,973			643,973
Exercise price of warrants		$0.60			$0.60
Fair values of warrants		143,000			143,000
Expected life					5 years
Notes payable | Unsecured promissory notes of $813,156
Debt Instrument [Line Items]
Secured senior convertible promissory note issued													813,156
Debt instrument, interest rate	15.00%		15.00%										15.00%
Number of note holders													2
Notes payable | Unsecured promissory notes, Repayment premium earned March 31 2015
Debt Instrument [Line Items]
Common stock issue to note holders	4,200,000
Estimated fair value	$0.33		$0.33										$0.33
Balance outstanding	$3,119,000		$3,119,000										$3,119,000

CONVERTIBLE_PROMISSORY_NOTES_S

CONVERTIBLE PROMISSORY NOTES - Summary of convertible promissory notes (Details) (Convertible promissory notes, USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Total, notes payable	$1,577,500	$1,477,500
Less unamortized discount	-36,949	-201,125
Less current portion (net of unamortized discounts)	-373,051	-947,987
Convertible promissory notes, net	1,167,500	328,388
Secured senior subordinated convertible promissory notes
Debt Instrument [Line Items]
Total, notes payable	892,500	892,500
Senior subordinated convertible promissory notes
Debt Instrument [Line Items]
Total, notes payable	$685,000	$585,000

CONVERTIBLE_PROMISSORY_NOTES_S1

CONVERTIBLE PROMISSORY NOTES - Summary of future maturities of outstanding convertible promissory notes (Details 1) (Convertible promissory notes, USD $)	Dec. 31, 2014
Convertible promissory notes
Debt Instrument [Line Items]
2015	$373,051
2016	1,167,500
Total	$1,540,551

CONVERTIBLE_PROMISSORY_NOTES_D

CONVERTIBLE PROMISSORY NOTES (Detail Textuals) (USD $)	12 Months Ended		1 Months Ended		9 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	31-May-14	Jan. 31, 2013	Jan. 31, 2013	Jan. 31, 2015	Dec. 31, 2012
						Note_Holder
Debt Instrument [Line Items]
Amortization of the debt discount	$693,975	$308,633
Warrants
Debt Instrument [Line Items]
Exercise price of warrants	$0.65	$0.62					$0.64
Secured senior subordinated convertible promissory notes
Debt Instrument [Line Items]
Secured senior convertible promissory note issued			492,500
Secured senior subordinated convertible promissory notes | Warrants
Debt Instrument [Line Items]
Term of warrant			5 years
Number of common stock called by warrants			985,000
Exercise price of warrants			$0.60
Fair values of warrants			217,500
Convertible promissory notes | Secured senior subordinated convertible promissory notes
Debt Instrument [Line Items]
Secured senior convertible promissory note issued			492,500	300,000	892,500
Conversion price				$0.60	$0.60
Debt instrument, interest rate				12.00%	12.00%
Balance outstanding	892,500	892,500
Amortization of the debt discount	283,273	129,282
Convertible promissory notes | Secured senior subordinated convertible promissory notes | Subsequent Event
Debt Instrument [Line Items]
Principal amount of notes						792,500
Principal amount of notes refused to extend the due date						100,000
Number of note holders						1
Convertible promissory notes | Secured senior subordinated convertible promissory notes | Warrants
Debt Instrument [Line Items]
Term of warrant	5 years		5 years
Number of common stock called by warrants	1,115,625		985,000
Exercise price of warrants	$0.75		$0.60
Fair values of warrants	217,225		217,500
Beneficial conversion feature	$45,066

CONVERTIBLE_PROMISSORY_NOTES_D1

CONVERTIBLE PROMISSORY NOTES (Detail Textuals 1) (USD $)	12 Months Ended		3 Months Ended	5 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2013	Jan. 31, 2014	Jun. 30, 2014	Jan. 31, 2015
Conversion price lesser of:
Amortization of the debt discount	$693,975	$308,633
Convertible promissory notes | Notes issued between May 2013 and July 2013
Debt Instrument [Line Items]
Senior subordinated convertible promissory notes issued			485,000
Conversion price lesser of:
Conversion price			$0.65
Specified percentage qualified transaction price			75.00%
Debt instrument, interest rate			7.00%
Balance outstanding	485,000	485,000
Amortization of the debt discount	91,408	875
Convertible promissory notes | Notes issued between May 2013 and July 2013 | Subsequent Event
Conversion price lesser of:
Principal amount of notes						450,000
Convertible promissory notes | Notes issued between May 2013 and July 2013 | Warrants
Conversion price lesser of:
Term of warrant			3 years
Number of common stock called by warrants			746,157
Percentage of conversion price			120.00%
Conversion price			$0.78
Fair values of warrants			92,283
Convertible promissory notes | Notes issued between September 2013 and January 2014
Debt Instrument [Line Items]
Senior subordinated convertible promissory notes issued				125,000
Conversion price lesser of:
Conversion price				$0.65
Specified percentage qualified transaction price				75.00%
Debt instrument, interest rate				7.00%
Balance outstanding	125,000	100,000
Amortization of the debt discount	16,409	1,721
Convertible promissory notes | Notes issued between September 2013 and January 2014 | Warrants
Conversion price lesser of:
Term of warrant				3 years
Number of common stock called by warrants				192,308
Percentage of conversion price				120.00%
Conversion price				$0.78
Fair values of warrants				22,000
Convertible promissory notes | Notes issued in June 2014
Debt Instrument [Line Items]
Senior subordinated convertible promissory notes issued					75,000
Conversion price lesser of:
Conversion price					$0.65
Specified percentage qualified transaction price					75.00%
Debt instrument, interest rate					7.00%
Balance outstanding	75,000	0
Amortization of the debt discount	4,200	0
Convertible promissory notes | Notes issued in June 2014 | Warrants
Conversion price lesser of:
Term of warrant					3 years
Number of common stock called by warrants					115,386
Percentage of conversion price					120.00%
Conversion price					$0.78
Fair values of warrants					$9,600

CAPITAL_LEASE_OBLIGATIONS_RELA2

CAPITAL LEASE OBLIGATIONS (RELATED PARTY) - Summary of components of capital lease obligations (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Capital Lease Obligation [Line Items]
Total capital lease obligations	$43,630	$53,916
Less current portion	-11,323	-10,286
Long-term portion	32,307	43,630
Equipment | $199,610 capital lease obligation on equipment, bears interest at 9.65% per annum, monthly in principal and interest installments of $2,704 and matures in May 2018
Capital Lease Obligation [Line Items]
Total capital lease obligations	$43,630	$53,916

CAPITAL_LEASE_OBLIGATIONS_RELA3

CAPITAL LEASE OBLIGATIONS (RELATED PARTY) - Summary of components of capital lease obligations (Parentheticals) (Details) (Equipment, $199,610 capital lease obligation on equipment, bears interest at 9.65% per annum, monthly in principal and interest installments of $2,704 and matures in May 2018, USD $)	12 Months Ended
	Dec. 31, 2014
Equipment | $199,610 capital lease obligation on equipment, bears interest at 9.65% per annum, monthly in principal and interest installments of $2,704 and matures in May 2018
Capital Lease Obligation [Line Items]
Capital lease obligation on equipment	$199,610
Lease bears interest per annum	9.65%
Principal and interest installments monthly payments	$2,704

CAPITAL_LEASE_OBLIGATIONS_RELA4

CAPITAL LEASE OBLIGATIONS (RELATED PARTY) - Summary of future minimum capital lease payments (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Leases [Abstract]
2015	$15,041
2016	15,041
2017	15,041
2018	6,267
Total minimum lease payments	51,390
Less amount representing interest	-7,760
Present value of minimum lease payments	43,630
Less current portion	-11,323	-10,286
Long-term portion	$32,307	$43,630

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Detail Textuals) (USD $)	1 Months Ended
	Jan. 31, 2010	Dec. 31, 2014	Dec. 31, 2013
	Clinic
Related Party Transaction [Line Items]
Related party payables		$290,567	$23,622
William Kirby, D.O., Inc
Related Party Transaction [Line Items]
Related party payables		290,567	23,622
Management Services Agreement | William Kirby, D.O., Inc
Related Party Transaction [Line Items]
Number of clinics in southern California	4
Related parties receivables		0	0
Medical Director Agreement | William Kirby, D.O., Inc
Related Party Transaction [Line Items]
Initial term of agreement	5 years
Annual payment for services	250,000
Related party payables		$20,833	$0

EQUITY_Summary_of_stock_option

EQUITY - Summary of stock option activity (Details) (Stock options, USD $)	12 Months Ended
	Dec. 31, 2014
Stock options
Number of Options
Outstanding at December 31, 2013	1,549,230
Granted	54,545
Exercised
Forfeited or Expired	-49,869
Outstanding at December 31, 2014	1,553,906
Exercisable at December 31, 2014	1,119,679
Vested and expected to vest at December 31, 2014	1,553,906
Weighted Average Exercise Price per Share
Outstanding at December 31, 2013	$0.45
Granted	$0.55
Exercised
Forfeited or Expired	$0.39
Outstanding at December 31, 2014	$0.46
Exercisable at December 31, 2014	$0.45
Vested and expected to vest at December 31, 2014	$0.46
Weighted Average Grant-Date Fair Value per Share
Outstanding at December 31, 2013	$0.44
Granted	$0.49
Exercised
Forfeited or Expired	$0.39
Outstanding at December 31, 2014	$0.44
Exercisable at December 31, 2014	$0.43
Vested and expected to vest at December 31, 2014	$0.44

EQUITY_Summary_of_warrant_acti

EQUITY - Summary of warrant activity (Details 1) (Warrants, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrants
Shares
Outstanding	6,508,415	3,150,434
Granted	2,049,447	3,562,914
Exercised
Expired or cancelled	-225,000	-204,933
Exercisable	8,332,862	6,508,415	3,150,434
Weighted average exercise price
Outstanding	$0.62	$0.64
Granted	0.61	0.73
Exercised
Expired or cancelled	1	0.93
Exercisable	$0.65	$0.62	$0.64
Weighted average remaining contractual life (in years), Outstanding			4 years 6 months
Weighted average remaining contractual life (in years), Granted	4 years 8 months 12 days	4 years
Weighted average remaining contractual life (in years), Exercisable	3 years 1 month 6 days	3 years 9 months 18 days

EQUITY_Summary_of_warrants_out

EQUITY - Summary of warrants outstanding and exercisable (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014
Warrant Exercise price $.37
Class of Warrant or Right [Line Items]
Number of Shares Under Warrants	128,840
Range of Exercise Prices	$0.37	$0.37
Expiration Date	2015
Warrant Exercise price $.37 | Weighted Average
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price	$0.37
Warrant Exercise price $.59-.78
Class of Warrant or Right [Line Items]
Number of Shares Under Warrants	915,651
Expiration Date	2016
Warrant Exercise price $.59-.78 | Minimum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$0.59
Warrant Exercise price $.59-.78 | Maximum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$0.78
Warrant Exercise price $.59-.78 | Weighted Average
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price	$0.77
Warrant Exercise price $.49-.78
Class of Warrant or Right [Line Items]
Number of Shares Under Warrants	3,103,481
Expiration Date	2017
Warrant Exercise price $.49-.78 | Minimum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$0.49
Warrant Exercise price $.49-.78 | Maximum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$0.78
Warrant Exercise price $.49-.78 | Weighted Average
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price	$0.63
Warrant Exercise price $.60-1.00
Class of Warrant or Right [Line Items]
Number of Shares Under Warrants	2,289,291
Expiration Date	2018
Warrant Exercise price $.60-1.00 | Minimum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$0.60
Warrant Exercise price $.60-1.00 | Maximum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$1
Warrant Exercise price $.60-1.00 | Weighted Average
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price	$0.68
Warrant Exercise price $.60-.65
Class of Warrant or Right [Line Items]
Number of Shares Under Warrants	1,895,599
Expiration Date	2019
Warrant Exercise price $.60-.65 | Minimum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$0.60
Warrant Exercise price $.60-.65 | Maximum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$0.65
Warrant Exercise price $.60-.65 | Weighted Average
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price	$0.60
Warrants Exercise price $.37-1.00
Class of Warrant or Right [Line Items]
Number of Shares Under Warrants	8,332,862
Warrants Exercise price $.37-1.00 | Minimum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$0.37
Warrants Exercise price $.37-1.00 | Maximum
Class of Warrant or Right [Line Items]
Range of Exercise Prices	$1
Warrants Exercise price $.37-1.00 | Weighted Average
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price	$0.65

EQUITY_Detail_Textuals

EQUITY (Detail Textuals) (USD $)

12 Months Ended

1 Months Ended

3 Months Ended

5 Months Ended

1 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

31-May-13

Mar. 31, 2013

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Dec. 31, 2014

Apr. 30, 2013

Jul. 31, 2014

Jan. 31, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Proceeds from exercise of stock options

$17,493

Number of earned common stock

4

Repayment premium rate

100.00%

Additional repayment premium rate

10.00%

Common Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares issued

13,636

145,455

423,061

Issue price of shares issued

$0.49

$0.49

$0.49

$0.49

Number of shares issued to lender

125,000

1,000,000

525,000

475,000

Number of redemption shares issued to lender

2,000,000

Number of common stock repurchased from lender

10,000

Repurchase price per share

$0.49

Common Stock | Private Placement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Sale of common stock in private placement

136,365

90,910

Proceeds from sale of common stock through private placement

75,000

50,000

Common Stock | Independent Directors

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares issued

270,000

Number of independent director

3

Common Stock | Consultants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares issued

153,061

Common Stock | Vendor

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares issued

10,500

Issue price of shares issued

$0.49

Common Stock | Non Executive Employee

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares issued as additional compensation

5,300

Non-qualified stock options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares issued pursuant to stock option exercised

35,700

Proceeds from exercise of stock options

$17,500

EQUITY_Detail_Textuals_1

EQUITY (Detail Textuals 1) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Mar. 31, 2013	Oct. 31, 2013	Jun. 30, 2013	Feb. 28, 2014	Jul. 31, 2013	Jan. 31, 2013
			Member				Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options	$17,493
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares purchase of common stock		54,545
Weighted average exercise price per share of the options granted		$0.55
Estimated fair value of stock option on issuance date		0
Aggregate intrinsic value of options exercised		0
Aggregate intrinsic value of options outstanding		21,000
Stock options | General and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation expense	136,000	69,000
Non-qualified stock options | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares purchase of common stock			20,000
Weighted average exercise price per share of the options granted			$0.49
Fair value assumptions, method used			Black-Scholes option-pricing model
Estimated fair value of stock option on issuance date			52,000
Value of common share (in dollars per share)			$0.49
Strike price			$0.49
Expected term			5 years
Risk free interest rate			0.63%
Expected volatility rate			73.00%
Expected dividend rate			0.00%
Number of members			3
Number of shares vesting 50% immediately			45,000
Percentage of vesting immediately			50.00%
Percentage of shares vesting each anniversary of grant date			25.00%
Non-qualified stock options | Employee of William Kirby, D.O., Inc.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares purchase of common stock			6,517	6,088
Weighted average exercise price per share of the options granted			$0.49	$0.55
Fair value assumptions, method used			Black-Scholes option-pricing model	Black-Scholes option-pricing model
Estimated fair value of stock option on issuance date			14,000	3,900
Value of common share (in dollars per share)			$0.49	$0.49
Strike price			$0.49	$0.55
Expected term			5 years	5 years
Risk free interest rate			0.63%	1.41%
Expected volatility rate			73.00%	63.00%
Expected dividend rate			0.00%	0.00%
Non-qualified stock options | Five members of medical advisory board
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares purchase of common stock			10,000
Weighted average exercise price per share of the options granted			$0.49
Fair value assumptions, method used			Black-Scholes option-pricing model
Estimated fair value of stock option on issuance date			13,400
Value of common share (in dollars per share)			$0.49
Strike price			$0.49
Expected term			5 years
Risk free interest rate			0.63%
Expected volatility rate			73.00%
Expected dividend rate			0.00%
Number of members			5
Percentage of vesting immediately			25.00%
Percentage of shares vesting each anniversary of grant date			25.00%
Non-qualified stock options | Five members of medical advisory board two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares purchase of common stock			10,000
Weighted average exercise price per share of the options granted			$0.55
Fair value assumptions, method used			Black-Scholes option-pricing model
Estimated fair value of stock option on issuance date			13,400
Value of common share (in dollars per share)			$0.49
Strike price			$0.49
Expected term			5 years
Risk free interest rate			0.63%
Expected volatility rate			73.00%
Expected dividend rate			0.00%
Number of members			5
Percentage of vesting immediately			25.00%
Non-qualified stock options | New members of medical advisory board
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares purchase of common stock					10,000
Weighted average exercise price per share of the options granted					$0.55
Fair value assumptions, method used					Black-Scholes option pricing method
Estimated fair value of stock option on issuance date					2,503
Value of common share (in dollars per share)					$0.49
Strike price					$0.55
Expected term					5 years
Risk free interest rate					1.07%
Expected volatility rate					64.00%
Expected dividend rate					0.00%
Percentage of shares vesting each anniversary of grant date					25.00%
Incentive stock options | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares purchase of common stock			13,264	2,513	212,413
Share based compensation vesting period					4 years
Weighted average exercise price per share of the options granted					$0.55
Fair value assumptions, method used					Black-Scholes option-pricing model
Estimated fair value of stock option on issuance date					53,200
Value of common share (in dollars per share)					$0.49
Strike price					$0.55
Expected term					5 years
Risk free interest rate					1.07%
Expected volatility rate					64.00%
Expected dividend rate					0.00%
Incentive stock options | Executive officers
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares purchase of common stock			24,041	7,327		54,545	112,727	61,225
Share based compensation vesting period						12 months	4 years	12 months
Weighted average exercise price per share of the options granted						$0.55	$0.55	$0.49
Fair value assumptions, method used						Black-Scholes option-pricing model	Black-Scholes option-pricing model	Black-Scholes option-pricing model
Estimated fair value of stock option on issuance date						$13,200	$28,100	$17,300
Value of common share (in dollars per share)						$0.49	$0.49	$0.49
Strike price						$0.55	$0.55	$0.49
Expected term						5 years	5 years	5 years
Risk free interest rate						1.57%	1.42%	0.67%
Expected volatility rate						61.00%	63.00%	73.00%
Expected dividend rate						0.00%	0.00%	0.00%
Number of executive officer							2

EQUITY_Detail_Textuals_2

EQUITY (Detail Textuals 2) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

5 Months Ended

31-May-14

Apr. 30, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

31-May-13

Mar. 31, 2013

Feb. 28, 2014

Jan. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Feb. 28, 2013

Aug. 31, 2013

Apr. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jan. 31, 2014

Dec. 31, 2012

Oct. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrant liabilities

$24,260

$116,690

$116,690

Secured senior subordinated convertible promissory notes

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Secured senior convertible promissory note issued

492,500

Tenant improvement secured loans

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Secured senior convertible promissory note issued

100,000

Unsecured promissory notes

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Secured senior convertible promissory note issued

300,000

Warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price of warrants

$0.65

$0.62

$0.62

$0.64

Value of common share (in dollars per share)

$0.49

$0.49

$0.49

Fair value assumptions method used

Black-Scholes option pricing model

Black-Scholes option pricing model

Expected dividend yield

0.00%

0.00%

Warrants | Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected life

3 years

3 years

Risk free interest rate

0.86%

0.58%

Volatility rate

46.00%

63.00%

Warrants | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected life

5 years

5 years

Risk free interest rate

1.73%

1.73%

Volatility rate

61.00%

72.00%

Warrants | Service provider

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

3 years

5 years

5 years

Vesting period of warrant

1 year

Number of common stock called by warrants

39,000

39,000

34,090

76,530

Exercise price of warrants

$0.78

$0.78

$0.65

$0.60

Fair values of warrants

900

4,300

4,300

Warrants | Service provider | General and administrative expense

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair values of warrants

7,800

20,500

Warrants | Employees

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

5 years

5 years

Number of common stock called by warrants

27,273

30,613

Exercise price of warrants

$0.65

$0.60

Fair values of warrants

8,200

Warrants | Employees | General and administrative expense

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair values of warrants

6,100

Warrants | Two employee

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

5 years

Number of common stock called by warrants

84,545

Exercise price of warrants

$0.65

Warrants | Two employee | General and administrative expense

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair values of warrants

19,400

Warrants | Consultants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

5 years

Number of common stock called by warrants

450,000

Exercise price of warrants

$1

Number of warrants cancelled

225,000

Warrants | Consultants | General and administrative expense

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair values of warrants

80,300

Warrants | Secured senior subordinated convertible promissory notes

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

5 years

Number of common stock called by warrants

985,000

Exercise price of warrants

$0.60

Fair values of warrants

217,500

Warrants | Tenant improvement secured loans

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

5 years

Number of common stock called by warrants

239,353

585,240

Exercise price of warrants

$0.60

$0.60

Fair values of warrants

53,200

145,900

Expected life

5 years

Warrants | Tenant improvement secured loans | Director

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock called by warrants

146,310

Warrants | Unsecured promissory notes

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

5 years

5 years

5 years

Number of common stock called by warrants

643,973

630,893

630,893

Exercise price of warrants

$0.60

$0.60

$0.60

Fair values of warrants

143,000

141,500

141,500

Warrants | Unsecured promissory notes | Director

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock called by warrants

97,174

97,174

Warrants | Private Placement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

5 years

5 years

Number of common stock called by warrants

170,457

170,457

Exercise price of warrants

$0.65

$0.65

Fair values of warrants

41,600

41,600

Warrants | Private Placement | Secured senior subordinated convertible promissory notes

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

5 years

5 years

5 years

3 years

5 years

Number of common stock called by warrants

186,537

375,000

186,537

115,386

186,537

Exercise price of warrants

$0.78

$0.75

$0.78

$0.78

$0.78

Fair values of warrants

89,500

9,600

Condition for number of shares issuable under warrant pursuant to conversion of debt

In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 100% of the number of conversion shares and the strike price adjusted to 120% of the conversion price.

Warrant liabilities

6,200

Warrants | Private Placement | Secured senior subordinated convertible promissory notes | Director

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock called by warrants

250,000

Warrants | Private placement in May, June And July 2013 | Secured senior subordinated convertible promissory notes

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

3 years

Number of common stock called by warrants

746,157

746,157

Fair values of warrants

91,400

91,400

Condition for number of shares issuable under warrant pursuant to conversion of debt

In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 100% of the number of conversion shares and the strike price adjusted to 120% of the conversion price.

Warrant liabilities

13,100

91,400

91,400

Warrants | Private placement from September 2013 to January 2014 | Secured senior subordinated convertible promissory notes

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of warrant

3 years

Number of common stock called by warrants

153,846

Exercise price of warrants

$0.78

Fair values of warrants

25,800

Condition for number of shares issuable under warrant pursuant to conversion of debt

In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 100% of the number of conversion shares and the strike price adjusted to 120% of the conversion price.

Warrant liabilities

$4,100

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES - Summary of aggregate minimum future payments required on operating leases (Details) (USD $)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$625,613
2016	574,981
2017	464,847
2018	193,741
2019	99,631
Thereafter	52,480
Aggregate minimum future payments	$2,011,293

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Detail Textuals)	12 Months Ended
	Dec. 31, 2014
Minimum
Operating Leased Assets [Line Items]
Percentage of annual escalation provisions	3.00%
Period for options renewal	3 years
Maximum
Operating Leased Assets [Line Items]
Percentage of annual escalation provisions	4.00%
Period for options renewal	5 years

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Detail Textuals 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
William Kirby, D.O., Inc
Operating Leased Assets [Line Items]
Rent expense relating to operating leases	$11,000	$42,000
Unrelated Third Party
Operating Leased Assets [Line Items]
Rent expense relating to operating leases	$639,000	$586,000

INCOME_TAXES_Components_of_pro

INCOME TAXES - Components of provision for income taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current
Federal
State	3,863	800
Total current tax	3,863	800
Deferred
Federal
State
Total	$3,863	$800

INCOME_TAXES_Summary_of_differ

INCOME TAXES - Summary of difference between income taxes at statutory rates and amount presented in financial statements (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Computed expected income tax benefit at federal statutory rates	34.00%	34.00%
Addition to (reduction in) income taxes resulting from:
State income taxes, net of federal benefit	6.00%	6.00%
Other
Valuation allowance	-40.00%	-40.00%
Total	0.00%	0.00%

INCOME_TAXES_Significant_compo

INCOME TAXES - Significant components of deferred taxes (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$5,900,000	$4,286,000
Other	1,668,000	708,000
Less valuation allowance	-7,568,000	-4,994,000
Net deferred tax assets

INCOME_TAXES_Detail_Textuals

INCOME TAXES (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Examination [Line Items]
Change in deferred tax assets valuation allowance	$2,570,000	$1,635,000
Domestic Tax Authority | Internal Revenue Service (IRS)
Income Tax Examination [Line Items]
Operating Loss Carryforwards	13,200,000	9,200,000
Income tax period under examination	3 years
State and Local Jurisdiction | California tax board
Income Tax Examination [Line Items]
Operating Loss Carryforwards	$10,900,000	$6,900,000
Income tax period under examination	4 years

SUBSEQUENT_EVENTS_Detail_Textu

SUBSEQUENT EVENTS (Detail Textuals) (Subsequent Event, USD $)	Mar. 31, 2015
Subsequent Event [Line Items]
Exchange rate for each warrant to common stock	0.4
Convertible promissory notes, net of current portion and unamortized discount	$1,167,500
Secured tenant improvement loans
Subsequent Event [Line Items]
Debt instrument, principal amount	100,000
Unsecured promissory notes
Subsequent Event [Line Items]
Debt instrument, principal amount	$1,350,000